University of Kentucky

UKnowledge
Theses and Dissertations--Veterinary Science

Veterinary Science

2015

GLUCOCORTICOID-INDUCED CHONDROCYTE CYTOTOXICITY AT
DOSES RECOMMENDED FOR INTRA-ARTICULAR THERAPY IN
HORSES
Wenying Zhu
University of Kentucky, wyingzhu12@gmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Zhu, Wenying, "GLUCOCORTICOID-INDUCED CHONDROCYTE CYTOTOXICITY AT DOSES RECOMMENDED
FOR INTRA-ARTICULAR THERAPY IN HORSES" (2015). Theses and Dissertations--Veterinary Science. 23.
https://uknowledge.uky.edu/gluck_etds/23

This Doctoral Dissertation is brought to you for free and open access by the Veterinary Science at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Veterinary Science by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Wenying Zhu, Student
Dr. James MacLeod, Major Professor
Dr. Daniel Howe, Director of Graduate Studies

GLUCOCORTICOID-INDUCED CHONDROCYTE CYTOTOXICITY AT DOSES
RECOMMENDED FOR INTRA-ARTICULAR THERAPY IN HORSES

_____________________________________________
DISSERTATION
_____________________________________________
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Agriculture, Food, and Environment
at the University of Kentucky
By
Wenying Zhu
Lexington, Kentucky
Director: Dr. James N. MacLeod, Professor of Veterinary Science
Lexington, Kentucky
2015

Copyright © Wenying Zhu 2015

1

ABSTRACT OF DISSERTATION

GLUCOCORTICOID-INDUCED CHONDROCYTE CYTOTOXICITY AT DOSES
RECOMMENDED FOR INTRA-ARTICULAR THERAPY IN HORSES
Intra-articular glucocorticoid injections are commonly used to treat synovitis
and osteoarthritis in horses. These agents are highly effective at relieving pain,
swelling, and other symptoms of joint inflammation. The drugs also have
therapeutic benefits by down regulating the expression of cytokines and protease
enzymes that participate in the degradation of articular cartilage. However,
detrimental effects on chondrocyte function and cell viability that is independent of
osteoarthritis pathogenesis have been described and linked to glucocorticoid use.
These side effects are both drug- and dose-dependent. This study tested the
hypothesis that manufacture recommended dosage levels of methylprednisolone,
betamethasone, and triamcinolone that are widely used in equine clinical practice
are cytotoxic to articular chondrocytes. Drug-induced chondrocyte cytotoxicity was
evaluated in monolayer cultures, cartilage explants, and equine fetlock joints. Total
RNA was isolated from control and IL-1β stimulated primary chondrocytes and
synoviocytes in culture. Changes in steady state mRNA for targeted gene transcripts
related to inflammation and normal cell function were measured using reverse
transcription and quantitative PCR. Inducible nitric oxide synthase activity was
evaluated using nitrite production. Drug-induced chondrocyte cytotoxicity occurred
at drug dosage levels frequently used in equine clinical practice. Both drug- and
dose-dependent effects on chondrocyte and synoviocyte gene expression were
observed. Maximum anti-inflammatory activities for the glucocorticoids were
observed at in vitro concentrations below manufacturer-recommended levels.
Results from this study suggest that lower glucocorticoid dose ranges for intraarticular therapy in horses should be validated to maximize the ratio of their
therapeutically beneficial anti-inflammatory efficacy against detrimental effects on
cell function and viability.

Keywords: Equine, Articular Cartilage, Corticosteroid, Chondrocyte
Cytotoxicity, Anti-inflammation
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Chapter I Background and Literature Review
I.

Importance of Osteoarthritis: both in horses and humans
Osteoarthritis (OA), a degenerative joint disease, is the most common

muscuoskeletal disease both in humans and horses. Lameness due to joint injury
and joint disease is the most prevalent cause of diminished function and poor
performance in racehorses. Several epidemiologic studies have documented the
substantial impact of joint disease. Thirty-six to fifty-two percent of racehorses up
to four years old have clinical sign of lameness (Jeffcott et al., 1982, Rossdale et al.,
1985). According to a study done at Cornell University between 1983 and 1990 on
equine patient admissions, 42% of racehorses older than 24 months with lameness
had clinical sign of OA (Fubini et al., 1999). Likewise, OA not only affects racehorses,
but also non-racing horses. A survey suggested that 60% of non-racing horses older
than 24 months with lameness had clinical sign of OA (Caron et al., 2003).
Osteoarthritis is also recognized as a major concern in human health, because of a
large number of people involved and its severe impact on quality of life. It affects
about 60% of men and 70% of women over the age of 65 (Sarzi-Puttini et al., 2005).
It is a common cause of long-term disability in many populations of middle aged and
older people (Praemer et al., 1999; Felson et al., 1995). Approximately 40% of
adults over 70 suffer from OA of the knee, 80% of people with OA have limitations in
movement, and about 25% cannot perform daily living activities (World Health
Organization and bone and joint decade, 2001).Osteoarthritis has significant health
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and quality of life implications for individuals, societies, and economies around the
world – problems that are expected to get even worse as with aging populations
(Brooks et al., 2002).

Osteoarthritis is first and foremost characterized by the ongoing destruction of
articular cartilage in diarthrodial joints. Although it may develop in any joint, areas
most commonly affected are weight bearing joints of the legs, including knees, and
hips in humans, or stifle, carpus, and fetlock joints in horses. Osteoarthritis may
result from injury, an abnormal growth pattern, or inherited factors. Mechanical
impact is recognized as an important parameter for all of these issues (Brandt et al.,
2009), and may also limit intrinsic joint repair mechanisms attempting to restore
joint function. Due to years of mechanical stress, cartilage extracellular matrix
components, which are responsible for the biomechanical properties of the tissue,
are broken down and the normal balance between their synthesis and degradation
is lost. Over time, the structural integrity of articular cartilage fails and joint
movement becomes increasingly painful and restricted.

II.

Joint Inflammation in Osteoarthritis

Osteoarthritis is characterized by changes in composition, structure and function
of the articular cartilage. Although articular cartilage degeneration followed by
erosion is the main identifying characteristic of OA, recent evidence supports a
newer perspective that OA is a whole joint disorder affecting all joint tissues
2

including all connective tissues within and around the joints. OA results from joint
degeneration, a process that includes degradation of the articular cartilage
accompanied by attempted repair of articular cartilage, thickening of the
subchondral bone, formation of subchondral bone cysts and osteophytes, and
variable degrees of inflammation of the synovium (Buckwalter et al., 1995, 1997,
2000, Gerwin et al., 2004) (Figure 1). These changes usually limit joint movement
and typically cause pain. Pain is the most common appearance of OA and the major
cause of lameness associated with the disease. It can be generated by two types of
factors: mechanical stimuli and inflammation. Mechanical stimulation may elicit
inflammation response through tissue injury (Rene et al., 2010). OA is a process of
changes of joint tissues responding to inflammatory mediators within the affected
joint. It is frequently associated with signs and symptoms of inflammation, such as
joint pain and swelling, leading to significant functional impairment and disability
(Felson et al., 2006). Inflammation, that occurs in response to mechanical irritation
and injury is central to the pathogenesis of OA and involves not only chondrocytes,
but also cells in the synovial membrane and subchondral bone. Inflammatory
cytokines, chemokines, and other inflammatory mediators, produced by the
synoviocytes and chondrocytes, can be measured in the synovial fluids of
osteoarthritis patients (Rainbow et al., 2012).
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Figure 1. Healthy and osteoarthritic joints (Adopted from: N. Gerwin, 2006).

The role of synovial membrane in joint inflammation
Osteoarthritis research is traditionally focused on the understanding of changes
on articular cartilage integrity and chondrocyte pathobiology.

The synovial

membrane changes are largely neglected. However, synovial membrane is an
important portion of the joint and synovial inflammation is an important component
of OA, contributing to the imbalance of chondrocyte catabolic and anabolic activities
(Loeser et al., 2006).
The synovial membrane is a vascular connective tissue that lines the
noncartilaginous surfaces within a joint cavity (Blom et al., 2007, Radin et al., 2001).
The synovial lining cells consist of two different cell types: type A and type B
synoviocytes. The two cell types execute different functions. Type A synoviocytes
are macrophage-like cells that can eliminate excess materials and potential
pathogens from the joint (Iwanaga et al., 2000; Blom et al., 2007). Type B
4

synoviocytes are fibroblast –like cells that are responsible for producing hyaluronan
(HA) which is the main component of synovial fluid. In a normal joint, these two
type of synoviocytes function together to maintain a healthy environment. However,
in pathologic conditions, type A synoviocytes can stimulate type B synoviocytes to
produce inflammatory mediators and matrix degrading enzymes.
Articular cartilage relies on adjacent tissues, such as subchondral bone and
synovial membrane, to help maintain the health of the chondrocytes. The synovial
membrane regulates molecules moving into and out of the joint space and maintains
the composition of synovial fluid (Scanzello et al., 2012). Synovial fluid not only is
important for reducing friction of joint movement, but also functions to transport
nutrients and oxygen to the cartilage (Blom et al., 2007; Hui et al., 2011). However,
the permeability of the synovial membrane can be altered when inflammation
occurs. This likely contributes to the decreased concentration of HA and lubricin in
synovial fluid. The level of HA has been reported to be elevated in concentration
during inflammation, and serum HA concentrations have been used as a marker of
synovitis (Goldberg et al., 1991).
Synovial inflammation is common in both early- and late-stage OA, although
they are generally of lower grade than those observed in rheumatoid arthritis (RA)
(Sellam et al., 2010). Moderate or marked inflammatory synovitis is present in
nearly 50% of the synovial membranes from patients with OA (Goldenberg et al.,
1982; Pearle et a. 2007). This condition is marked by dramatically increased
secretion of pro-inflammatory cytokines and proteolytic enzymes from synoviocytes
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(Fernandes et al., 2002; Goldring et al., 2007; Revell et al., 1988; Ashraf et al., 2011;
Bondeson et al., 2010). Pro-inflammatory cytokines, including interleukin 1β (IL-1β),
interleukin 6, and tumor necrosis factor-α (TNF-α), are reported to mediate the
cartilage degeneration and joint pain associated with OA (Sellam et al., 2010;
Wassilew et al., 2010). The most extensively studied cytokines are IL-1β and TNF-α,
which can induce expression of matrix degrading proteases, suppress matrix
synthesis and promote cartilage catabolism (Aigner et al., 2006; Goldrin et al. 2009).
Matrix metalloproteinases (MMPs), including MMP-1, MMP-3, and MMP-13, can be
detected in OA synovial fluid samples, although at significantly lower levels than in
RA joints (Pozgan et al., 2010).
Articular cartilage in osteoarthritis
Articular cartilage is a highly specialized, avascular, and aneural connective
tissue that forms the smooth gliding surface of the diarthrodial joints (Figure 2).
Cartilage allows the frictionless motion of the joint, in which it absorbs and
dissipates loading stress. It is largely an extracellular matrix (ECM), which is
synthesized by sparsely distributed resident cells, named chondrocytes. ECM is
composed mainly of a high concentration of proteoglycans (aggrecan), collagen
fibers, non-collagenous non-proteoglycaneous proteins, and a large amount of water
(Heinegard et al., 1992). The integrity of articular cartilage is altered to some degree
in all joints with OA (Figure 3). Cartilage matrix components are broken down and
normal balance of synthesis and degradation is lost. A net loss of proteoglycan
content is one of the hallmarks of all stages of osteoarthritic cartilage degeneration
(Figure 3) (Mankin et al., 1971).
6

A

B

Figure 2. Diarthrodial joint (A, adopted from www.studyblue.com) and structure of
articular cartilage (B, adopted from php.med.unsw.edu.au).

A

B

Figure 3. Cartilage in healthy and osteoarthritic joints. The normal cartilage has
smooth articular surface (A) and OA cartilage shows fissuring of articular surface
(B). Proteoglycans abundant in cartilage matrix was stained with red color using
Safranin-o. Histological appearance of healthy articular cartilage showed a good
Safranin-o staining. Safranin-o stain was decreased in OA cartilage.
7

Chondrocytes, the only cell type in articular cartilage, are responsible for the
balanced turnover of the ECM and maintenance of structural integrity in
cartilaginous tissues (Aigner et al., 2006). During the osteoarthritic disease process,
cellular reaction patterns of chondrocytes are changed. It can respond to joint injury
or biomechanical perturbation by undergoing cell death, proliferation, or
phenotypic modulation. Compared to normal cartilage, chondrocytes alter their
gene expression profile in OA (Aigner et al., 2001). It is largely reported that
chondrocytes have the capacity to up-regulate synthetic activity or increase the
production of inflammatory mediators and matrix degradation enzymes, which are
also produced by other joint tissues (Goldring et al., 2009). Chondrocytes obtained
from OA tissues actively express MMPs, IL-1β, TNF-α, IL-6, IL-8, and a number of
other genes that enhance or modulate inflammatory and catabolic responses,
inducible nitric oxide synthase(iNOS) and cyclooxygenase 2 (COX-2) (Loester et a.,
2012; Pelletier et al., 2001). These molecules act within cartilage in an autocrine or
paracrine manner to promote a catabolic state, which leads to progressive cartilage
degradation in OA joints (Attur et al., 1998). Chondrocytes also produce a large
amount of NO when stimulated by IL-1β and TNF-α. NO inhibits the synthesis of
extracellular matrix components such as type II collagen and proteoglycans, but
increases activity of MMPs (Aigner et al., 2002).
8

Pro-inflammtory cytokines and matrix metalloprotease
It is believed that different inflammatory molecules in the development of OA
play an important role. IL-1β and TNF-α produced by activated synoviocytes,
mononuclear cells or by chondrocytes are the 2 major cytokines in the pathogenesis
of OA (Fernandes et al., 2002). IL-1β is primarily synthesized as a precursor and
released in the active form (Mosley et al., 1987). The catabolic effects of IL-1β are
multiple. It not only can stimulate its own production, induce the expression of
MMPs and other catabolic genes, but also inhibit the synthesis of matrix
constituents such as collagens and proteoglycans (Pelletier et al., 2008). This
cytokine also plays important roles in normal joints, including stimulation of the
turnover of extracellular matrix (Pelletier et al., 2008). Although TNF-α has only
been detected in OA articular tissue at low levels, it also appears to be an important
mediator of cartilage matrix degradation and a pivotal cytokine in inducing synovial
membrane inflammation (Fernandes et al., 2002). IL-1 and TNF- α can stimulate the
mitogen-activated protein kinase (MAPK) pathways and nuclear factor κB (NF-κB)
pathway which are central inflammatory pathways in OA (Saklatvala et al., 2007).
These kinase cascades lead to the expression of many inflammatory genes and MMP
genes which facilitate the degradation of several ECM proteins, such as collagens,
proteoglycans, fibronectin, link protein and other matrix proteins which are critical
for normal cartilage function and integrity (Malemud et al., 2004).
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The matrix degrading enzymes found in the OA joint include aggrecanases and
collagenases, which are members of the MMP family. These include stromelysin-1
(MMP-3), collagenase -1(MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13),
and aggrecanases (Clark et al., 1998; Woessner et al., 1991). These proteinases are
very much involved in the cartilage matrix degradation in OA (Poole et al., 1995).
Cartilage matrix degradation in early OA may be due to aggrecanase and MMP-3,
which degrade aggrecan. Then increased activity of MMP-13 is highly efficient at
degrading type II collagen (Dahlberg et al., 2000). Once the collagen network is
degraded, the damage to the cartilage structure cannot be reversed.
The main objectives in the management of OA are to reduce symptoms,
minimize functional disability, and limit progression of the structural changes.
Therefore, controlling joint inflammation and immediate damage to cartilage, as
well as minimizing long-term degenerative structure changes, are important
objectives of OA therapy.

III.

Anti-inflammatory therapies commonly used for synovitis and
osteoarthritis
There are a number of treatments available for synovitis and osteoarthritis.

Aims of these treatments are to relieve the pain, prevent the cytokines and matrix
degrading enzymes from compromising the articular cartilage, and finally return the
joint to normal as quickly as possible. Non-pharmacological therapies and medical
treatments are discussed in this section.
10

Non-pharmacological therapies to reduce inflammation
Non-pharmacological therapies can be used as the first step, both in humans
and horses, for joint injury and disease treatment (Roos et al., 2012). These
treatments can be used alone or in combination with medical and surgical
treatments (Figure 4).

Few
Surgery

Some

Pharmacological therapies

Education, exercise and weight control

All

Figure 4. The osteoarthritis treatment pyramid. Non-pharmacological treatments
can be used for all patients. Pharmacological therapies are useful for some of the
patients. Few patients need to have the surgery to maintain the joint function.

Physical therapy and rehabilitation are commonly used non-pharmacological
treatments for horse synovitis and osteoarthritis. Cold hydrotherapy might be
extremely useful as a primary treatment immediately after an acute joint injury. It is
indicated to retard the inflammatory processes and reduce edema (Hickman J,
1964). After 48 hours, hot hydrotherapy might help to relieve pain and reduce
tension in inflamed tissues (Adams OR, 1974; Lehmann JF et al., 1982; Michlovitz SL
11

et al., 1996; Prentice WF et al., 1994). Swimming is the closest treatment to nonweight bearing motion, which is practiced in human sports medicine and in horse
sport medicine (McIlwraith et al., 2001). It is used in the convalescent period with
joint injury to maintain the horse’s condition while relieving joint trauma.
Recently, there also has been considerable use of treatments such as
electromagnetic therapy, electrostimulation, and low level laser for various
musculoskeletal conditions including traumatic joint disease. The value of
extracorporeal shock save therapy (ESWT) has been demonstrated with
experimental osteoarthritis in the horse (Frisbie et a., 2009).

It significantly

reduced the degree of lameness in horses, although no disease-modifying effects
were evident (Frisbie et a., 2009). The effects of non-surgical defocalized carbon
dioxide laser therapy (DLT) on acute synovitis and capsulitis was evaluated
(Lindholm et al., 2002). Although no control was established, observer-blind and
prospective studies still observed beneficial effects of DLT on reducing the degree of
lameness, which was comparable with conventional intra-articular medical
treatments (Lindholm et al., 2002).

Current commonly used anti-inflammatory drug therapy
Drug therapy is one of the most utilized treatments for OA in equine practice.
Evaluating therapeutic efficacy has largely focused on improvements in pain
management and joint function. The mainstay of medical treatment has included
systemic non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular (IA)
corticosteroids, viscosupplementation, and chondroprotectants (Goodrich et al.,
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2006). The following section discusses systemic medical treatment of OA, followed
by IA and other topical therapies.
Systemic treatment of OA
NSAIDs are by far the most commonly used drugs in this category. The effect of
NSAID is primarily the inhibition of cyclooxygenase (COX) enzymes in the
arachidonic acid cascade, thus inhibiting prostaglandins production (Higgins et al.,
1984). There are two forms of cyclooxygenase: constitutive COX 1 and inducible
COX 2.

It is reported that COX 2 enzyme may be primarily responsible for

inflammatory response and COX 1 is responsible for producing prostaglandins
involved in regulating normal cellular processes, such as protection of mucosal
barriers in the gastrointestinal tract (Meade et al., 1993). The identification of COX
1 and COX 2 may explain, the variability of efficacy, as well as toxicity, of different
NSAIDs. Most of the older NSAIDs have been shown to inhibit both COX 1 and COX 2.
Moreover, some of them, such as aspirin, indomethacin and piroxicam, are reported
to be more potent inhibitors of COX 1 than COX 2, which means that they more
negatively

affect

normal

physiological

function

than

beneficially

inhibit

inflammation (May et al., 1996). Selective COX 2 inhibitors have been developed and
demonstrated a superior gastrointestinal safety profile in humans, while providing
comparable anti-inflammatory potency (Chen et al., 2008). However, selective COX
2 inhibitors are known to cause cardiovascular (CV) events (McGettigan et al., 2006),
and its gastrointestinal protective benefits may be negated if the patient is also
taking aspirin (Chan et al., 2007). Selective COX 2 inhibitors have also become
available for the treatment of OA in horses, but traditional nonselective NSAIDs are
13

still routinely used. Table 1 summarizes dosages and ways of administration for the
most commonly used NSAIDs in horses.

Name of Drug

Route of Application

Phenylbutazone Oral
Flunixin

Oral or IV

Carprofen

Oral or IV

Ketoprofen

IV or IM

Vedaprofen

Oral

Meloxicam

Oral

Naproxen

Oral or IV

Table 1. Overview of the most commonly used NSAIDs with their route of
administration.

Other systemic treatments for OA in horses include intramuscular (IM)
polysulfated glycosaminoglycans (PSGAG), IV or oral sodium hyaluronate (HA), and
neutraceuticals.

PSGAGs alter OA progression by sustaining or promoting

chondrocyte metabolic activity and inhibiting the detrimental effects of cytokines or
prostaglandins on cartilage. HA has anti-inflammatory effects in the joint. Horses
treated with HA have reduced lameness, better synovial membrane scores, and a
reduction in prostaglandins in joints compared to joints of horses receiving saline
14

(Goodrich et al., 2006). Neutraceuticals are used to treat horses suffering from OA
or other chronic joint disorders and in most cases contain mixtures of chondroitin
sulfate and glucosamine.

These compounds are supposed to have a disease-

modifying effect. There has been controversy about the potential usefulness of these
compounds in horses since these products are not FDA controlled (Goodrich et al.,
2006).
Local treatment of OA
Intra-articular glucocorticoids are commonly used and can be extremely
effective for the therapeutic management of OA symptoms. Glucocorticoids are
powerful anti-inflammatory agents that strongly suppress the immune response.
However, glucocorticoid use became controversial because of side effects,
particularly on steroid-induced deterioration of articular cartilage, which also
known as steroid arthropathy. There now seems to be common agreement that if
used judiciously, intra-articular glucocorticoid therapy can be extremely beneficial.
Mechanism of glucocorticoids, side effects, and type of corticosteroid used are
discussed in detail in the following section.
Hyaluronic acid (HA), also called hyaluronan, is a large nonsulphated
glucosaminoglycan and synthesized by fibroblast-like synoviocytes of the synovial
membrane (Howard et al., 1996). It is an important component of the joint fluid and
serves various functions, such as viscoelasticity of the synovial fluid and boundary
lubrication of the articular cartilage (Scanzello et al., 2012). HA is also an important
component in articular cartilage matrix and can be locally produced by
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chondrocytes. It has been extensively used as intra-articular treatment in horses as
viscosupplementation and anti-inflammatory agent (Goodrich et al., 2006). The
combination of intra-articular glucocorticoids and HA is popular in equine practice,
as it may permit the reduction of the dose of glucocorticoids and may counteract the
possible deleterious effects of these drugs on the cartilage (Caron et al. 2005).

IV.

Intra-articular glucocorticoids: mechanisms of action and side effects

As noted above, glucocorticoids are potent anti-inflammatory agents widely used
in therapeutic applications for osteoarthritis (Todhunter et al. 1998, Goodrich et al.
2006 and Stitik et al. 2006). Glucocorticoids exert their effects by binding to
glucocorticoid receptors (GR) localized in the cytoplasm of target cells. Central to
the action of glucocorticoids is the interaction of glucocorticoid molecules with the
cytoplasmic glucocorticoid receptor, in response to which a vast number of
intracellular events are entrained. The efficacy of glucocorticoids in alleviating
inflammatory disorders results from the pleiotropic effects of the glucocorticoid
receptor on multiple signaling pathways (Adcock et al. 2000, Smoak et al. 2004, and
De Bosscher et al. 2003). Within the cell, glucocorticoid acts in three ways: direct
and indirect genomic effects and nongenomic mechanisms (Buttgereit et al 1998
and Rhen et al. 2005). First, the glucocorticoid receptor complex moves to the
nucleus, and binds as a homodimer to DNA sequences called glucocorticoidresponsive elements (GRE) or negative glucocrticoid-responsive elements (nGRE)
(Smoak et al, 2004 and Rhen et al. 2005), thereby facilitating or inhibiting
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transcription (Figure 5). This process is highly dynamic and has demonstrated to
increase the synthesis of certain anti-inflammatory proteins, including lilpocortin-1,
IL-1 receptor antagonist, and IL-10, but is also related to glucocorticoid-induced
side effects (Smoak et al, 2004 and Rhen et al. 2005). Second, glucocorticoid
receptor sequesters and interacts with other transcription factors, such as nuclear
factor-kappa B (NF-kB) and activator protein-1 (AP-1), to suppress transcription
(Figure 5). The third mechanism is called non-genomic actions, which are mediated
through membrane-associated receptors and second messengers (Buttgereit et al
1998).
Although these medications effectively decrease inflammation, side effects
independent of OA pathogenesis have been identified (Fubini et al. 2001). Cartilage
collected from joints treated with glucocorticoids have pathological changes that
include chondrocyte cell death, reduced proteoglycan content and rate of synthesis,
decreased collagen synthesis, and an increase in the percentage of water
(Chunekamrai et al. 1989, Richardson et al. 2003). Over time, these changes
compromise the structural integrity and biomechanical properties of articular
cartilage.

In regards to bone metabolism, glucocorticoids have been found to

inhibit osteoblasts which function in bone production and increase osteoclast
activity which aid in bone resorption, thereby creating a bone that is more
susceptible to the development of osteoporosis or fractures. Another side effect of
glucocorticoids includes avascular necrosis and altered bone repair (Bitto et al,
2009). The effects of glucocorticoids on bone metabolism and structure has been
extensively studied in humans and lab animals, but not in horses. The therapeutic
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use of glucocorticoids for OA is limited by these side effects, especially during longterm treatment.
Methylprednisolone acetate (MPA), betamethasone, and triamcinolone are
three commonly used intra-articular corticosteroids in horses (Caron et al. 2005).
Although these drugs have strong anti-inflammatory activities, some detrimental
effects have been reported. Many studies have been conducted to observe the
beneficial and side effects of MPA on cartilage, subchondral bone, and synovium.
Side effects were reported both in vivo and in vitro studies (Frisbie et al. 1998,
MacLeod et al. 1998, Shoemaker et al. 1992). It appears that lower doses inhibit
inflammation while maintaining the normal joint metabolism (Todhunter et al.
1996). Further studies are needed to accurately identify the best MPA dose in the
horse. A study looked at one dose of MPA (100 mg administered in the middle
carpal joint) and found no significant side effects on subchondral bone, but indicated
further research with multiple drug compounds at varying doses need to be
examined to draw conclusions regarding glucocorticoid effects on bone structure
and metabolism

in the equine (Murray et al, 2002).

There is no significant

detrimental effect observed in the cartilage following administration of
betamethasone in horse joints (Foland et al. 1994). However, side effects like
suppression of proteoglycan synthesis are detected with in vitro work (Frean et al.
2002). Triamcinolone was reported to inhibit the inflammatory molecules without
side effects on cartilage extracellular matrix (Celeste et al. 2005, Dechant et al. 2003,
Frisbie et al. 1997, Kawcak et al. 1998). According to the above finding, the specific
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type of glucocorticoid used and the concentration achieved following administration
plays an important role on side effects of these drugs on cartilage.

Figure 5. Mechanisms of transactivation and transrepression actions of
glucocorticoids and glucocorticoid receptor in the cell.

V.

New

anti-inflammatory

pharmacologic

agents:

dissociative

glucocorticoids
As previously mentioned, the genomic action of glucocorticoids can be divided
into two processes: transactivation and transrepression. It is widely accepted that
the numerous desirable anti-inflammatory and immunomodulating effects of
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glucocorticoids are mediated by their transrepression properties (Lin et al., 2002),
whereas most of the adverse side effects are mediated through transactivation
mechanisms (Schacke et al., 2002). Significant side effects of glucocorticoids lead to
the development of several new compounds. Dissociative glucocorticoids, a novel
group of glucocorticoid ligands, bind selectively to the glucocorticoid receptor and
differentially recruit downstream cofactors (Catley et al. 2007). These compounds
cause a receptor conformation that prefers monomer glucocorticoid receptor and
protein interaction rather than homodimer glucocorticoid receptor DNA binding
(Stahn et al., 2007). As a consequence, they can inhibit the activity of MAPK and NFκB pathways by protein-protein interaction like glucocorticoids, while having fewer
side effects than glucocorticoids (Cogylan et al. 2003, Humphrey et al. 2006, and
Owen et al. 2007). Some dissociative glucocorticoids have a similar level of antiinflammatory activity compared to prednisolone, both in vitro and in vivo (Cogylan
et al. 2003, Humphrey et al. 2006, and Owen et al. 2007). This list of potential
alternative compounds tested in various in vitro and in vivo studies are provided in
Table 2.
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Drug

In

vitro In vivo animal model Human clinical trial

testing

testing

Dissociative Non-steroidal Compounds
AL-438

✓

✓

NT

LGD-5552

✓

✓

NT

ZK 216348

✓

✓

Phase II (Atopic Dermatitis)

Compound A

✓

✓

NT

PF-803

✓

✓

Phase II (rheumatoid
arthritis)

Dissociative Steroidal Compounds
RU-

✓

✓

NT

VBP1

✓

✓

NT

VBP15

✓

✓

Phase I (Duchenne muscular
dystrophy

Compounds

Table 2. Potential alternative therapeutic dissociative compounds for treating
inflammatory diseases. “✓” means has already been completed. “NT” stands for not
tested.

Dissociative non-steroidal compounds
AL-438 (Coghlan et al., 2003; Elmore et al., 2001) and LGD-5552 (Miner et al.,
2007; Lopez et al., 2008) are nonsteroidal glucocorticoid receptor ligands which
bind the glucocorticoid receptor with specificity and relatively high affinity. In vitro
experiments indicate that AL-438 and LGD-5552 both effectively repress the
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production of TNF-α or IL-1β induced IL-6 and E-selectin levels similar to steroids
(Coghlan et al., 2003; Elmore et al., 2001; Miner et al., 2007; Lopez et al., 2008).
These two compounds were also tested in rat models showing desirable antiinflammatory effects and a promising lack of adverse effects, such as without
affecting glucose or bone metabolism (Coghlan et al., 2003; Elmore et al., 2001;
Miner et al., 2007; Lopez et al., 2008).
Compound A (Bosscher et al., 2005; Dewint et al., 2008) and ZK216348
(Schacke et al., 2004) are also non-steroidal glucocorticoid receptor ligands which
demonstrated anti-inflammatory effects with reduced detrimental side effects both
in vitro and in vivo.
Dissociative steroidal compounds
The first dissociative steroidal compounds were discovered by Roussel-Uclaf
(RU), including a series of RU-steroidal compounds. These RU compounds were
determined to retain transrepression action with weakly transactivation properties
in vitro but not in vivo (Belvisi et al., 2001; Schacke et al., 2007; Chen 2008).
In recent years, an increasing number of dissociative glucocorticoids have been
described. A very interesting substance is, for example, VBP1 and VBP15
(anecortave desacetate) (Baudy et al., 2012). VBPs are Lazaroid ∆-9,11 analogs,
which were developed originally as nonglucocorticoid steroids with effects on cell
membranes and tested clinically for neuroprotection by the inhibition of lipid
peroxidation (Taylor et al., 1996; Bracken et al., 1997; Kavanagh and Kam, 2001).
Lazaroids have been reported to inhibit acute inflammation through the
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suppression of inducible nitric oxide synthase (iNOS) (Altavilla et al., 1999), TNF-α
(Altavilla et al., 1998), and NF-kB (Fukuma et al., 1999). In the recent study by
Baudy et al (2012), VBP1 and VBP15 were tested for anti-inflammatory efficacy and
side effects both in vitro and in vivo. The results showed potent inhibition of TNF-α
induced NF-kB signaling in cell reporter assays, and a reduction of muscle
inflammation and improvements in multiple muscle function assays in two mouse
models of muscular dystrophy. Meanwhile, VBP15 exhibited lower affinity for
mineralcorticoid receptor than the other VBPs and maintained comparable antiinflammatory efficacy to prednisolone (Heier et al. 2013). Accordingly, VBP15
shows promise as a potentially safer therapeutic agent for chronic inflammatory
disorders. Currently, VBP15 is undergoing the Phase I clinical trial.
VI.

Articular chondrocyte culture

Primary articular chondrocytes and cell lines
Chondrocyte culture experiments are widely used for investigating the
intracellular and molecular events associated with chondrocyte biological function
and activation. Several culture models have been proved useful for studying
chondrocyte function, such as primary cultures of animal or human chondrocytes,
and cell lines from chondrosarcoma. However, chondrocyte cell lines cannot be
entirely substituted for primary cultures, as major cell biology differences have been
shown between normal and transformed chondrocytes (Mallein-Gerin et al. 1993,
Stokes et al. 2001).
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Primary articular chondrocyte culture methods
Many in vitro culture methods have been developed for the investigation of
chondrocyte and cartilage biological properties, including monolayer cultures,
several forms of three-dimensional (3D) aggregate cultures systems, and cartilage
explants models (Adolphe et al., 1992; Tew et al., 2008). Monolayer culture is a
commonly used in vitro method to grow chondrocytes and generate sufficient cell
numbers for experimental analyses. However, chondrocytes cultured using this
approach may undergo a characteristic process of cellular dedifferentiation, marked
by a decrease in type II collagen synthesis and aggrecan core protein expression and
the induction of type I collagen expression (Darling et al., 2005; Goessler et al., 2004;
Goessler et al., 2005). This phenomenon is influenced to some extent by seeding
density and is accelerated by growth in medium supplemented with serum and by
passage (Hering et al., 1994; Ronziere et al., 1997; Matmati et al., 2012). Threedimensional aggregate cultures systems, which include nonadherent aggregates,
pellets, and cells embedded in an artificial material made of alginate, agarose, or
collagens (Thirion et al., 2004), maintain their differentiated phenotype better than
that of monolayer cultures. However, cell proliferation is limited so that large
numbers of primary cells are needed for each experiment. In addition, extracting the
cells from the artificial matrix can be technically challenging (Thirion et al., 2004).
Experiments designed using a combination of chondrocyte culture methods,
supported by in vivo studies where possible, facilitates biological discovery.
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VII.

Knowledge gaps, hypothesis, and specific aims.
Many important knowledge gaps remain, both with regard to OA pathogenesis

and treatment. For equine patients, basic questions such as the optimal use of
established medical therapies continue to be debated. Even with the extensive use
of intraarticular corticosteroids on equine patients, objective data on dosedependent relationships between anti-inflammatory efficacy and chondrocyte
toxicity are limited.

The objective of this dissertation was to evaluate these

relationships for three commercial glucocorticoids that are widely used in clinical
settings for the management of equine synovial joint inflammation. The hypothesis
tested was that methylprednisolone, betamethasone, and triamcinolone that are
widely used in equine clinical practice are cytotoxic to articular chondrocytes.
Dose-dependent anti-inflammatory profiles of methylprednisolone, betamethasone,
and triamcinolone in articular chondrocytes and synoviocytes were defined and
compared. Glucocorticoid-induced chondrocyte cytotoxicity in monolayer culture,
articular cartilage explants, and in vivo was evaluated.

Copyright © Wenying Zhu 2015
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Chapter II Materials and Methods
I.

Cell isolation and culture

Equine articular chondrocytes and explants
1. Articular cartilage collection and chondrocyte cell isolation
Full-thickness articular cartilage was harvested immediately postmortem from
normal synovial joints of adult horses. For each horse, chondrocytes were
enzymatically isolated from the cartilage matrix and cryopreserved as described
previously (Nixon et al., 1992; Stewart et al., 1998). Articular cartilage was minced
with a scalpel and digested overnight in basal digestion medium [OPTI-MEM, 5%
fetal bovine serum, 1% L-glutamine, 25 μg/mL L-ascorbic acid phosphate (Wako
Chemicals USA, Richmond, VA), 50 U/mL penicillin, and 50 μg/mL streptomycin)],
and 0.75% collagenase II (Worthington Biochemicals,Freehold, NJ). After digestion,
the cell suspension was filtered through a sterile funnel containing a base layer of
44µm mesh (Nylon membrane, Millipore, NY) and 4 layers of cheesecloth into 50 ml
conical tubes.

The isolated chondrocytes were rinsed with PBS solution and

counted. Cell viability was assessed using trypan blue staining with an automated
(ViCell, Beckman Coulter) analyzer. An experiment was continued only when the
proportion of viable cells was > 95%.
2. Chondrocyte monolayer culture
Monolayer chondrocyte cultures were established at a seeding density of 0.4 x
106 cells/well in 6-well plates and cultured for 5 days in Opti-MEM (Gibco, 1105826

021) with 5% fetal bovine serum, 1% L-glutamine, 25 µg/ml L-ascorbic acid
phosphate, 50 U/ml penicillin and 50 µg/ml streptomycin. On day 6, the confluent
cultures were washed twice with serum-free Opti-MEM medium, followed by
culturing in Opti-MEM medium without serum for another 5 days.

Various

experiments were started on day 11. Chondrocytes used to assess glucocorticoidsinduced cytotoxicity were seeded in 96 well plates at a density of 1 x 104 cells/well
and cultured in the same Opti-MEM with 5% fetal bovine serum for 24 hours.
Medium was changed every 2-3 days.
3. Chondrocyte aggregate culture
Nonadherent aggregate cultures were maintained in hydrogel-coated 6-well
plates to prevent cell adhesion and maintain cartilage phenotype. Three million
cells were placed in each well in 5 ml of medium and cultured at 37 oC with 5%
carbon dioxide at saturated humidity in Opti-MEM serum free medium,
supplemented with 1% L-glutamine, 25 µg/ml L-ascorbic acid phosphate, 50 U/ml
penicillin and 50 µg/ml streptomycin. During the first 72 h of culture, the floating
cells spontaneously came together to form clearly visible aggregates.

At each

medium change, spent medium was aspirated and centrifuged at 300 rcf for 5
minutes. Aspirated cells were resuspended in 5 ml of fresh medium and returned to
the appropriate wells. Various experiments were started on day 11.
4. Cartilage explants culture
Articular cartilage was aseptically collected as full-thickness explants from
normal synovial joints of adult horses between the age of 3 and 4 years. A 6-mm
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diameter biopy punch instrument was used to maintain approximate uniformity in
size and weight of each sample. The explants were washed in sterile PBS solution
with 1% penicillin-streptomycin, 2.5ug/ml amphotericin B, and placed in 6-well
plates within 2 hours of collection, then incubated in Opti-MEM medium
supplemented with 5% (v/v) FBS, L-ascorbic acid (25 µg/ml), L-glutamine (300
µg/ml), penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37oC in 5% CO2
and 95% humidity. Explants were adapted to culture conditions for 24 hours before
experimental variables were applied.
Equine synovial fibroblast isolation and culture
Synovial membrane tissue was collected from normal synovial joints of three
horses. Synovial fibroblasts were prepared by a method described in Kojima et al
(2002). Briefly, tissues were dissociated by mincing and then digested overnight
with 1 mg/ml type I collagenase (Sigma, St.Louis, MO) in Dulbecco’s modified
Eagle’s medium (DMEM) in a humidified 5% CO2 incubator at 37oC. Dissociated
cells were cultured in 75 cm2 culture flasks in DMEM supplemented with 10% fetal
bovine serum (FBS), L-glutamine (2mM), 50 U/ml penicillin and 50 µg/ml
streptomycin. At greater than 95% confluency, the adherent synovial fibroblasts
were passaged by digestion with 0.05% trypsin/EDTA. For all experiments, passage
4 cells were plated into 6-well plates (0.4x106 cells/well) in DMEM containing 10%
FBS for 24 h. After seeding, the synovial cells were cultured for an additional 24 h in
DMEM with 2% FBS and then incubated with or without various experimental
stimuli.
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II.

Experimental variables in tissue culture

Pro-inflammatory stimuli with IL-1β and LPS
To stabilize baseline cell function and levels of gene expression, chondrocyte
monolayers were cultured for 10 days and synovial fibroblasts for 24 hours prior to
stimulation. After the adaptation period, cells were treated with medium containing
equine recombinant IL-1β (R&D system) (1 ng/ml or 10 ng/ml), or Escherichia coli
lipopolysaccharide (LPS) (1 ng/ml, 10 ng/ml, or 100 ng/ml) for either 24 hours or
72 hours. At the end of the treatment period, the culture medium was collected to
analyze nitric oxide levels and the cells were lysed for total RNA isolation.

Glucocorticoids
1. Molecular structures
Methylprednisolone sodium succinate (MPS) was purchased from PharmaciaUpjohn (Kalamazoo, MI). Betamethasone 21-phosphate disodium (BPD) and
triamcinolone acetonide (TA) were purchased from Sigma (St. Louis, MO). VBP1 was
synthesized by Bridge Organics (Kalamazoo, MI) (Figure 6).
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BPD

MPS

VBP1

TA

Figure 6. Molecular structures of MPS, BPD, TA and VBP1.

2. Concentrations and solubility
MPS and BPD were prepared at the initial concentration levels of 10-2 M in
Opti-MEM. Serial dilution was performed to reach the target concentrations. TA
and VBP1 are both water insoluble compounds. Stock solutions at a concentration
of 10 mM were prepared for these two compounds using dimethyl sulfoxide (DMSO;
Sigma, St.Louis, MO) as a diluent.

Serial dilutions were used to reach target

experimental concentrations. The final volume of DMSO in culture medium was
below 1% (v:v).
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3. Evaluation of glucocorticoids administration protocols
a) Timing of methylprednisolone treatment relative to IL-1β stimulation
Chondrocyte aggregates and synovial fibroblasts were treated with a dose of
10-4 M methylprednisolone (Pfizer) with or without 1 ng/ml equine recombinant IL1β (R&D system). Three methylprednisolone (MPS) treatment models: pre-treated
with MPS (IL-1β 24h; MPS 36h); post-treated with MPS (IL-1β 24h; MPS 12h);
treated together with MPS and IL-1β (IL-1β 24h; MPS 24h) were tested.
Chondrocyte aggregates were pre-cultured in Opti-MEM medium without any
stimulus for 10 days and synovial fibroblasts were pre-cultured in DMEM medium
without any stimulus for 24 hours to adapt to culture conditions. After pre-culturing,
cells were re-fed with fresh medium with 1 ng/ml IL-1β or 10-4 M MPS alone, 1
ng/ml IL-1β and 10-4 M MPS, or fresh medium without any treatment for 12 hours.
Cell culture medium was changed and cells were re-fed with medium containing
MPS alone, IL-1β and MPS, or without any treatment for other 12 h. Cells in the MPS
pre-treatment group were continued culturing in the medium with IL-1β and MPS
for 12 more hours. Cells and medium in the other two groups were collected for the
following study. Cells stimulated with IL-1β alone were used as positive controls,
and cells without any stimulation were used as negative controls for this study.
b) Anti-inflammatory efficacy
Methylprednisolone acetate (MPS) from Pfizer, betamethasone 21-phosphate
disodium (BPD) from Sigma, and triamcinolone acetonide (TA) from Sigma were
used for this study. VBP1 was donated by Bridge Organics. The following treatment
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groups were investigated: control treatment with no corticosteroid treatment and
free of recombinant equine interleukin-1β(IL-1β); control treatment with DMSO
without corticosteroid treatment and free of IL-1β;IL-1β stimulation containing only
1ng/ml IL-1β without corticosteroid addition; MPS (10-4 or 10-6 M), BPD (10-4 or 106

M), TA (10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M) only without IL-1β stimulation; MPS

(10-4 or 10-6 M), BPD (10-4 or 10-6 M), TA (10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M)
each with 1ng/ml IL-1β added to the medium (Figure 7). The drug concentrations
were extrapolated from dosages used clinically and the previous cytotoxicity study.
After incubation with treatment, chondrocytes and spent medium were harvested.
All medium were stored at -70 oC until analyzed. Before collection, chondrocytes
were rinsed twice using PBS, scraped from the culture plate, and stored at -70 oC.
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Figure 7. Timing and sequence of drug treatment and IL-1β stimulation for
evaluating the anti-inflammatory efficacy of methylprednisolone, betamethasone,
triamcinolone, and VBP1 treatment on articular chondrocytes.
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III.

RNA isolation
Total RNA was isolated from chondrocytes and synovial fibroblasts using the

QIAGEN RNeasy Mini Kit (QIAGEN). After cells were rinsed with D-PBC, total RNA
was isolated according to manufacturer’s protocol. Total RNA quantity and purity
were assessed with a NanoDrop ND-1000.

RNA integrity assessments were

performed with a BioAnalyzer 2100 (Agilent, Eukaryotic Total RNA Nano Series II)
and were deemed suitable for downstream applications based upon RNA integrity
number >8, 28S:18S rRNA ratio >1.8, UV 260:280 ratio >1.8, and UV 260:230 ratio
>1.7.
IV.

Reverse transcription and Real-time qPCR
Differential expression of nine genes, interleukin-1 β (IL-1β), interleukin-6 (IL-

6), inducible nitric oxide synthase (iNOS), matrix metalloproteinase 3 (MMP3),
matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 13 (MMP13), tissue
inhibitor of metalloproteinases 2 (TIMP2), type II collagen (COL2A1) and hyaluronic
acid synthase 2 (HAS2), was analyzed using quantitative polymerase chain reactions
(RT-qPCR) (Table 3). Briefly, total RNA was reverse-transcribed into cDNA using an
oligo-dT primer with the Promega Reverse Transcription System (Promega, cat. no.
A3500). Total RNA (0.5 µg) was diluted in 39 µl nuclease-free water, and combined
with 41 µl reverse transcription master mix: 3 µl (20 U/ µl)avian myeloblastosis
virus (AMV) reverse transcriptase, 4 µl oligo dT primer (0.5 µg/ µl), 2 µl RNAsin (40
U/ µl), 8 µl dNTP (10 mM), 8 µl AMV buffer, and 16 µl MgCl2 (25 mM) (Promega,
Madison, WI), for each reverse transcription reaction. Samples of cDNA were then
stored at -20 oC until further analyzed.
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Quantitative “real-time” PCR (7900HT Fast Real-Time PCR Systems, Applied
Biosystems, Foster City, CA) was performed using TaqMan Gene Expression Master
Mix (Applied Biosystems) and intron-spanning primer/probe sets (Assays-byDesign, Applied Biosystems) designed from equine genomic sequence data
(Ensembl – http://www.ensembl.org/Equus_caballus/index.html; UCSC Genome
Browser – http://genome.ucsc.edu). Equine-specific RPLPO, EIF2B2, TMF1, IL-1β,
IL-6, iNOS, MMP3, MMP9, MMP13, TIMP2, COL2A1, and HAS2 primer/probe sets
were designed for this purpose. Given thought to the gene’s stability, efficiency, CT
range, and CT values compared to target genes, endogenous control genes were
used on the target gene plates. Large ribosomal protein (RPLPO), eukaryotic
translation initiation factor 2B (EIF2B2), TATA element modulatory factor (TMF1)
and hypoxanthine phosphoribosyltransferase (HPRT) were selected as endogenous
control genes because they showed the greatest stability for the sample set as
defined by the geNorm reference gene application (data not shown). Amplification
efficiencies were measured by the default fit option of LinRegPCR (LinRegPCR 7.0, J.
M. Ruijter and C. Ramakers, Academic Medical Center, Amsterdam, the Netherlands)
while maintaining the cycle threshold as a data point within the measured
regression line. Mean efficiencies for each gene across the whole experimental
groups were utilized for data analysis. Relative expression levels of target genes
were normalized to the relative quantities of endogenous control genes using
geometric mean with the geNorm VBA applet.
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Eukaryotic translation
initiation factor 2B
Hypoxanthine
phosphoribosyltransferase
Large ribosomal protein
TATA element modulatory
factor
Interleukin-1 β
Interleukin-6
Inducible nitric oxide
synthase
Matrix metalloproteinase 3
Matrix metalloproteinase 9
Matrix metalloproteinase
13
Tissue inhibitor of
metalloproteinases 2
Type II collagen
Hyaluronic acid synthase 2

Gene
Symbol
EIF2B2

Forward Primer

Reverse Primer

TCTGTGCTCCTATGTTCAAGCTTT

TTCTTCAAGCAGCCACAAACTTGT

HPRT

GCTGAGGATTTGGAAAAGGTGTTT

CTCCCATCTCCTTCATCACATCTC

RPLPO
TMF1

CTGATTACACCTTCCCACTTGCT
GCGAAGCTGCTGAAAGTCA

AGCCACAAATGCAGATGGATCA
GCCTCCCTTTTATCCAGTTCTCAT

IL-1β
IL-6
iNOS

CCGACACCAGTGACATGATGA
GGATGCTTCCAATCTGGGTTCAAT
GCGTTACTCCACCAACAATGG

ATCCTCCTCAAAGAACAGGTCATTC
TCCGAAAGACCAGTGGTGATTTT
CCAGATCCGGAAGTCATGCTTTC

MMP3

TIMP2

GCAGAAAACATACTTCTTTGTAGAGGAC GATAGCCTGGCTCCATAGATTGT
AA
CGCAAGCCGATATCGTCATC
CCATCGAAGGGATACCCATCTC
GAGCATCCTTCCAAAGACCTTATCT
GGATAACCTTCCAGAATGTCATAACC
A
CTGGACGTTGGAGGGAAGAAG
CCGTTCCCATCGGCCTTT

COL2A1
HAS2

CTGGCTTCAAAGGCGAACAAG
CAGAGCACTGGGACGAAGT

MMP9
MMP13

GCACCTCTTTTGCCTTCTTCAC
CAGGGTCAAGCATGGTATCTGAAT

Table 3. Primer nucleotide sequences used in RT-qPCR assays for genes described in the study
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Gene Name

V.

Nitric oxide production
For measurement of nitrite in the cell supernatants, chondrocytes and synovial

fibroblasts were plated into the wells of a 6-well plate at a density of 0.4 x 106
cells/well in phenol red free Opti-MEM containing 5% FBS or phenol red free DMEM
containing 2% FBS and incubated for 24 h in the presence or absence of IL-1β, with
or without treatment. Nitrite concentrations were measured in cell supernatants as
an indicator of NO production using a commercially available Griess reaction kit
(Cayman, Ann Arbor, MI, USA). Assay was performed according to the
manufacturer’s recommendation.

VI.

Glucocorticoid-induced chondrocyte cytotoxicity

In vitro analysis
1. Culture methods
Primary articular chondrocytes were seeded in 96-well plates at a density of 1
x 104 cells/cm2. The cultures were maintained in Opti-MEM medium supplemented
with 5% (v/v) FBS, L-ascorbic acid (25 µg/ml), L-glutamine (300 µg/ml), penicillin
(100 units/ml), and streptomycin (100 µg/ml), and incubated at 37oC in 5% CO2 and
95% humidity for 24 hours to adapt to culture conditions.
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2. Dose-and time-dependent effects of glucocorticoids
Once adapted to culture conditions, chondrocytes were washed 3 times in DPBS solution and placed in fresh Opti-MEM medium (control) or medium containing
MPS, BPD, or TA in varying concentrations in 96-well plates with 4 replicates.
Triamcinolone acetonide powder was dissolved in 2-hydroxypropal-β-cyclodextrin
(HC) (Sigma-Aldrich, St Louis, MO). The percentage of HC in culture media was kept
at levels no higher than 2%, according to the cytotoxicity assay for HC solution in
chondrocytes. The concentrations of MPS, BPD and TA included levels routinely
used in clinical practice (Table 4). Chondrocytes were treated with MPS, BPD, or TA
for 3, 6, 12, 24 or 72hours. Catilage explants were also treated with previously
mentioned drug at the same concentration levels for 72 hours.
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Concentration (M)

MPS

2x10-8

2x10-7

2x10-6

2x10-5

2x10-4

4x10-4

6x10-4

1.6x10-3

2x10-3

2x10-2

BPD

2x10-7

2x10-6

2x10-5

2x10-4

2x10-3

4x10-3

6x10-3

1.2x10-2

4x10-2

1x10-1

TA

5x10-9

5x10-8

5x10-7

5x10-6

1x10-5

2.3x10-5

5x10-5

9x10-5

2x10-4

1x10-1

Table 4. Concentrations of methylprednisolone, betamethasone, and triamcinolone used to evaluate the glucocorticoidinduced chondrocyte cytotoxicity in chondrocyte cell culture and cartilage explants.
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Drug

3. Assessing cell viability
a) Chondrocyte monolayer cell culture
Chondrocytes

cytotoxicity

assay

was

performed

using

the

3-(4,5-

dimethylthiazol-2yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2Htetrazolium inner salt (MTS) method using a commercially available kit (CellTiter 96
Aqueous one Solution Cell Proliferation Assay; Promega, Madison, WI, USA)
according to the manufacturer's instruction. This method has shown to be an
accurate indicator of cell viability by measuring mitochondrial NADPH or NADHdependent dehydrogenase activity. The MTS tetrazolium compound is directly
reduced by cellular NADH and NADPH to generate a colorimetric reaction. Briefly,
chondrocyte cells were seeded in 96 well plates at a density of 1 x 104 cells/well and
cultured in the Opti-MEM with 5% fetal bovine serum.
Chondrocyte cell viability was assessed after 3h, 6h, 12h, 24h and 72h
culturing with methylprednisolone, betamethasone, or triamcinolone respectively.
The cells were incubated with 20 µl of CellTiter 96 Aqueous one Solution for 3h at
37°C in a humidified atmosphere of 5% CO2. Plates were read on a microplate
spectrophotometer at 490 nm. The cells were evaluated regularly for morphological
changes. Data are expressed as the percentage of viable cells compared to control
samples.
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b) Cartilage tissue
After 24 hours pre-culture, explants were washed 3 times with D-PBS and refed with fresh media containing different concentrations of glucocorticoid drugs.
After 72 hours treatment, the cell culture medium was removed and explants were
washed 3 times in D-PBS solution.
The LIVE/DEAD viability/cytotoxicity kit for mammalian cell from Molecular
Probe was used to simultaneously detect live and dead cells. It achieves this by
utilizing two fluorescent labels; calcein-AM is metabolised by living cells to produce
a green fluorescent substrate, ethidium homodimer enters cells whose membranes
have been compromised and emits a red fluorescence. Glucocorticoid treated
explants were incubated individually with 1 ml PBS containing 10 μM calcein-AM
and 2 μM ethidium homodimer at 37°C for 30 min, and washed again in PBS,
mounted onto slides and viewed by confocal microscopy. Data are expressed as the
percentage of viable cells compared to control samples.

In vivo analysis
1. Animals
Nine horses at 3-4 years of age were studied (Table 5). All horses had a thorough
physical, lameness and radiographic examination of their metacarpal-phalangeal
and metatarsal-phalangeal (fetlock) joints before entry into the study. All horses
included in the study were free of both clinical and radiographic evidence of
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osteoarthritis and severe joint lesions. Horses were stabled on treatment days and
were allowed free exercise in a paddock on non-treatment days. All procedures for
this study were approved by the Animal Care and Use Committee at University of
Kentucky.
Experimental groups

Methylprednisolone

Betamethasone

Triamcinolone

Horse ID

Gender

Age (Y)

I-4

M

4

N-124

F

4

I-5

M

4

J-4

M

4

J-7

M

4

J-11

M

4

J-14

M

4

J-16

M

4

J-17

M

4

Table 5. Horse ID, gender and age for nine horses in each treatment group.

The nine horses were randomly assigned into the three treatment groups:
methylprednisolone, betamethasone, or triamcinolone treatment. Each treatment
group had 3 horses. The same drug was administered to the left front and left hind
fetlock joint of each horse, with the contra-lateral fetlock (right front, right hind)
receiving saline. This design results in a total of 6 replicates for each medication
with a further division of 3 applications per drug in the front fetlock and 3
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applications of the drug in the rear fetlock (Figure 8). The same treatment was
administered a total of two times, separated by an interval of one month.

Figure 8. Experimental design for intra-articular corticosteroid drug treatment in
nine horses. Each experimental group had 3 horses and each horse received two
injections with the same drug at 4 weeks interval. The left front and hind fetlock
joints were received corticosteroid injections, with the contra-lateral fetlocks
receiving saline.

2. Medicating joints
Fetlock joints at the time of injection were aseptically prepared by cleaning the
area with 70% EthOH and 2% Chlorhexidine using standard aseptic procedures to
minimize the potential of contaminating bacteria at the injection site.

After

preparation of the injection site, the appropriate volume of drug or saline was
injected into the joints.

Intra-articular injections of methylprednisolone,
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triamcinolone, and betamethasone were administered in the fetlock joint by a
licensed veterinarian at the upper limit of the treatment range as recommended by
the manufacturer. Drug-treated fetlock joints were received either 80 mg/joint of
methylprednisolone (Depo-Medrol), 12 mg/joint of betamethasone (Celeston), or 9
mg/joint of triamcinolone (Kenalog) individually (Table 6).

The contra-lateral

paired joints receiving the same amount of saline were used as controls.
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Commercial product
concentration

Triamcinolone
acetonide

10 mg/ml

Kenalog
Betamethasone
Celeston, Soluspan
Methylprednisolone
acetate

3 mg betamethasone
acetate, 3 mg
betamethasone sodium
phosphate, total 6
mg/ml
40 mg/ml

Intra-articular
dose for
proposed
experiment
9 mg/joint

Volume of
drug
(ml/joint)

12 mg/joint

2 ml

0.25

2.25 ml

80 mg/joint

2 ml

0.25

2.25 ml

0.9 ml

Volume of Total volume of
amikacin solution injected
(ml/joint) into joint
(ml/joint)
0.25
0.9 +0.25 + 1.1 ml
saline =2.25 ml

Depo-Medrol
Table 6. Volumes and concentrations of steroid drug solutions injected into horse fetlock joints.
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Drug
(Generic name,
Trade name)

3. Sample collections
Three days after the second injection, all horses were humanely euthanized
using commercial sodium pentobarbital euthanasia solution (Beuthanasia D,
Intervet). All tissue samples were collected postmortem. The fetlock joint was
dissected free from surrounding skin and subcutaneous tissues and in its entirety
isolated by transecting the proximal phalangeal and third metatarsal/metacarpal
bone with a band saw within 1 h after euthanasia. After opening, the joints were
inspected visually to exclude macroscopic pathology.

Subsequently, articular

cartilage plugs were collected perpendicular to the articular surface from 2
predefined locations on the proximal articular surface of the first phalanx using a 6mm diameter biopsy punch to maintain approximated size and weight uniformity of
each sample (Brama et al. 2009). One cartilage plug was collected from the dorsal
edge of the articular surface (site 1, Figure 9a, b). This site is exposed to dynamic,
intermittent peak-type loading other than the weight bearing during standing or
moving at slow speed (Figure 9c, Brama et al. 2001). A second cartilage plug was
harvested from the mid-region of the joint cavity (site 2, Figure 9a, b). This site is
constantly loaded whenever the limb is weight bearing, but it is not exposed to the
peak loads and shear forces to which site 1 is exposed (Figure 9c, Brama et al. 2001).
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Proximal phalanx

Site 1

a

Site 2
b

Normal weight-bearing

Hyperextension due to peak
loading

Site 1
Site 2

Site 1

Site 2
c

Figure 9. Anatomical sampling sites of articular cartilage plugs from the lateral
proximal articular surface of the proximal phalangeal bone. The articular cartilage
plugs (diameter 4 mm) were taken the dorsal edge of the articular surface of the
proximal phalanx (site 1) and the mid-region of the joint cavity (site 2). Site 1
exposed to dynamic, intermittent peak-type loading other than the weight bearing
during standing or moving at slow speed. Site 2 is the consistently weight bearing
position, but experiences lower absolute forces than site 1 (Brama et al. 2001).

4. Analysis of cell death
Cell viability within treated and control samples was evaluated immediately
after sample collections. Two section vertical slices 1 mm thick were cut through
each articular cartilage sample with a scalpel and incubated in 1 ml PBS containing 2
μM calcein-AM and 5 μM ethidium homodimer at 37°C for 30 min.

Confocal

fluorescence imaging (Leica TCS SP5) using 495 nm excitation and separation of
green (515 nm) and red (635 nm) fluorescence was used to visualize live and dead
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cells, respectively. A 10 x objective was used and six images (1.5 x 1.5 mm2) were
combined to obtain one of the entire slice. To quantify cell viability, the images were
analyzed using Image J (National Institute of Health, Maryland) as described
previously (Natoli et al. 2008). Percent viability was measured over a square area
defined by the full thickness of the explants (Figure 10 and 11).

Superficial layer
4 mm

Deep zone

Joint surface of proximal phalanx

Sample trimming to 1 mm thick slice

Articular surface

Tide mark
Calcified cartilage
Subchondral bone

Superficial zone
Middle zone
Deep zone

Visualize using Confocal Microscope

Stain with 2µM Calcein AM
5 µM EthD-1 for 30 min

Figure 10. Articular cartilage sample collection, dissection and staining. The
articular cartilage plugs (diameter 4 mm) were taken perpendicular to the articular
surface and down to the calcified cartilage from 2 predefined locations on the joint
surface of the proximal phalanx using 4 mm diameter biopsy punch. Samples were
trimmed to 1 mm thick slice and incubated in 1 ml PBS containing 2 μM Calcein-AM
and 5 μM EthD-1. Confocal microscope was used to visualize the live and dead cells.
Cartilage schematic image was taken from Geistlich Surgery.
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1.5 mm area for imaging
Begin
End

30 um

10 x objective, 6 sections were imaged,
each imaged area was 5 µm thick

6 images per sample

Live cells with green staining

Dead cells with red staining

Figure 11. Visualization with Confocal Microscope. The imaging area was 1.5 x 1.5
mm2. A 10 x objective was used to observe the samples and six images (1.5 x 1.5
mm2) were combined to obtain one sample. Live cells were stained with green color
and dead cells were stained with red color.
VII.

Statistical analysis
The data are expressed as mean +/- sem. Statistical analysis was done using

one-way analysis of variance followed by Turkey’s multiple comparison procedure.
P < 0.05 was considered statistically significant.
Data for in vivo study were analyzed using the General Linear Model procedure
(GLM procedure) of the SAS software. Each treated or untreated fetlock joint of
horse was considered as one block. The model included horse, block and their
interactions as covariates, and a treatment as a primary variable of interest. Data
were analyzed by use of ANOVA. Significance was defined as values of p-value<0.05.
Copyright © Wenying Zhu 2015
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Chapter III Results
I.

Establish an in vitro glucocorticoid treatment model
In order to develop a cell culture model for studying the effects of

glucocorticoids on primary equine articular chondrocytes, length of pre-culture,
pro-inflammatory stimuli, and timing of treatments were compared.
Establish a chondrocyte culture model with stable gene expression pattern.
Three genes including the housekeeping gene RPLPO were investigated by
quantitative RT-PCR. Following normalization to steady state levels RPLPO mRNA,
time-dependent changes in the expression of MMP3 and MMP9 were evaluated over
14 days in culture. The relative mean expression levels of each gene were compared
between chondrocytes prior to seeding (defined as 1.00) and cultured chondrocytes
at seven time points (days 1, 2, 3, 5, 7, 10, 14). The expression levels genes exhibited
dramatic changes during the culture period. As shown in Figure 12, MMP3 and
MMP9 exhibited higher expression levels in the early culture period than those in
the late culture period. The relatively stable expression of MMP3 was observed after
5 days culturing (Figure 12). MMP9 had relatively stable expression after 10 days
culturing (Figure 12). The similar gene expression patterns were observed in both
aggregate and monolayer cultures for two genes.
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1.5

MMP3 mRNA
relative expression

1.2
0.9
0.6
0.3
0.0

1.2
0.9
0.6
0.3

Days of culture

14

10

7

5

3

1

14

10

7

5

3

2

1

0.0
2

MMP9 mRNA
relative expression

1.5

Days of culture

Figure 12. Changes over time of MMP3 and MMP9 mRNA levels in monolayer
and aggregate
cultures of primary equine articular chondrocytes. Steady state
mRNA levels for MMP3 and MMP9 genes were measured using quantitative RT-PCR,
and normalized to RPLPO. Each value represents the mean+/-SEM with three
replicates.

Comparing the effects of IL-1β and LPS stimulation on pro-inflammatory gene
expression in primary articular chondrocytes and synovial fibroblasts.
Both IL-1β and LPS have been applied to stimulate the inflammatory response
in joint tissues in published studies. In order to establish an appropriate model of
joint inflammation, the expression levels of IL-6 and MMP13 were evaluated in
primary articular chondrocytes and synovial fibroblasts following IL-1β and LPS
stimulation (Figure 13). This experiment was used to compare the efficacy of IL-1β
and LPS on stimulating the inflammatory response in these two cell types. IL-1β
and LPS both significantly (p<0.05) stimulated these two gene expressions in
chondrocytes and synovial fibroblasts after 24 or 72 hours stimulation. IL-1β was
the more potent of stimulus than LPS, especially for synovial fibroblasts. More than
100-fold differences were observed between IL-1β and LPS stimulated gene
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expression levels of IL-6 and MMP13 in synovial fibroblasts. Comparing two
different concentrations (1ng/ml or 10ng/ml) of IL-1β, no significant difference was
identified (p>0.05).
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Figure 13. Changes of IL-6 and MMP13 gene expression in primary articular
chondrocytes (A) and synovial fibroblasts (B) exposed to different concentrations of
IL-1β and LPS. Cells were stimulated with recombinant equine IL-1β (1ng/ml or
10ng/ml) or LPS (1ng/ml, 10ng/ml, or 100ng/ml) for 24
or 72 hours. Steadystate mRNA levels of IL-6 and MMP13 were measured by RT-qPCR, and normalized
to the expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT
and TMF1 for synovial fibroblasts. IL-1β was the more potent of stimulus, but both
significantly (p<0.05, *) stimulated inflammatory responses in two cell types. No
significant difference was identified between two different concentrations of IL-1β.
Data are expressed as mean+/- SEM of three biological replicates.

53

Comparing differential expression of six genes in chondrocyte aggregate and synovial
fibroblasts culture with three different sequences of methylprednisolone treatment
relative to IL-1β stimulation.
In order to study the anti-inflammatory effects of glucocorticoids on joint
tissues, chondrocyte aggregate and synovial fibroblast inflammatory culture models
were established. Three methylprednisolone (MPS) treatment models: pre-treated
with MPS (IL-1β 24h; MPS 36h); post-treated with MPS (IL-1β 24h; MPS 12h);
treated together with MPS and IL-1β (IL-1β 24h; MPS 24h), were tested in
chondrocytes and synovial fibroblasts. The relative mean expression levels of each
gene were compared between cells with methylprednisolone treatment and control
cells with IL-1β stimulation alone. The three treatment models all significantly
(p<0.05) inhibited IL-1β, IL-6, iNOS, MMP3, MMP13 gene transcriptions stimulated
by IL-1β (2- 5-fold, Figure 14). The transcription levels of IL-1β, IL-6, iNOS, MMP3,
MMP13, COL2A1 (chondrocytes), HAS2(synovial fibroblasts) were also compared
among these three different treatment models. Significant differences were not
identified among three models (p>0.05).
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A: Articular chondrocytes

B: Synovial fibroblasts
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Figure 14. Effects of timing of glucocorticoid treatment on the expression of marker
genes related to inflammation and normal cell function in primary articular
chondrocytes (A) and synovial fibroblasts (B). Three methylprednisolone (MPS)
treatment models: pre-treated with MPS (IL-1β 24h; MPS 36h); post-treated
with MPS (IL-1β 24h; MPS 12h); treated together with MPS and IL-1β (IL-1β 24h;
MPS 24h), were tested in chondrocytes (A) and synovial fibroblasts (B). Steadystate mRNA levels were measured for each gene by RT-qPCR, and normalized to the
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and
TMF1 for synovial fibroblasts. The three treatment models all significantly (p<0.05,
*) inhibited pro-inflammatory gene transcriptions stimulated by IL-1β. Significant
differences were not identified between the treatment groups. Data are expressed
as mean+/- SEM of three biological replicates, with IL-1β positive control cells
defined as 1.00.
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II.

Dose-dependent effects of glucocorticoids on the expression of proinflammatory genes for synoviocytes and chondrocytes
Inflammation is central to the pathogenesis of osteoarthritis, responsible for

both the clinical symptoms and progressive destruction of articular cartilage
through increased production of cytokines and degradative enzymes such as matrix
metalloproteinases. Controlling inflammation, therefore, is an important therapeutic
goal and a major beneficial effect of glucocorticoid administration.
Pro-inflammatory gene expressions in primary articular chondrocytes and synovial
fibroblasts with glucocorticoid treatment.
To study the effects of glucocorticoids, steady-state mRNA levels of 5 proinflammatory genes were tested using quantitative RT-PCR. As previously reported
(Richardson et al., 2000), IL-1β increased steady-state mRNA of IL-6, IL-1β, MMP3,
MMP13 and iNOS dramatically in primary articular chondrocytes and synovial
fibroblasts. Methylprednisolone(MPS) (10-4M or 10-6M) significantly (p<0.05)
inhibited IL-6, IL-1β, MMP3, and MMP13 gene expression in both cell types, as well
as iNOS in chondrocytes, when compared to control cells with IL-1β stimulation
alone (Figure 15). These decreases ranged over the tested two doses range from
30% to 80% (Figure 15). Comparing the effects of two different doses of MPS on
pro-inflammatory gene transcriptions, no significant difference was observed
between these two concentrations (p>0.05).
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The similar results were observed in betamethasone (BPD) and triamcinolone
(TA). BPD (10-4M or 10-6M) significantly suppressed IL-6, IL-1β, MMP3, MMP13 and
iNOS gene transcriptions in chondrocytes (Figure 16A), IL-1β and MMP13 in
synovial fibroblasts as well (Figure 16B). However, no significant difference was
observed between the two BPD concentrations (p>0.05). TA (10-5M or 10-6M) also
significantly suppressed IL-6, MMP3, MMP13 and iNOS gene transcriptions in
chondrocytes (Figure 17A), IL-6, IL-1β and iNOS in synovial fibroblasts as well
(Figure 17B). The same as MPS and BPD, no significant difference was observed
between the two TA concentrations (p>0.05).

57

A: Articular chondrocytes

B: Synovial fibroblasts
1.2

0.9

*
0.6

*

*

**

*

**
*

0.3

*

0.9

*
0.6

*

* *

*

*

**

0.3

iN
OS

M

M

P1
3

P3
M
M

IL
-1


IL
-6

iN
O
S

M

M

P1
3

P3
M
M

IL
-1


0.0
IL
-6

0.0

Relative Expression

Relative Expression

1.2

Figure 15. Effect of two different concentrations of methylprednisolone (MPS) on
expression of pro-inflammatory marker genes in primary articular chondrocytes (A)
and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL-1β
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β
12 hours prior to MPS treatment. The cells were then refed with medium containing
both IL-1β and MPS for another 12 hours. Steady-state mRNA levels for IL-6, IL-1β,
MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized to the
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and
TMF1 for synovial fibroblasts. Anti-inflammatory activities of MPS were evaluated at
concentration levels of 10-4 M and 10-6 M . Cells treated with MPS showed
significant (p<0.05, *) changes in gene expression compared to control cells with IL1β stimulation alone. No significant difference was observed between the two
different MPS concentrations. Data are expressed as mean+/- SEM of three
biological replicates, with IL-1β positive control cells defined as 1.00.
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Figure 16. Effect of two different concentrations of betamethasone (BPD) on
expression of pro-inflammatory marker genes in primary articular chondrocytes (A)
and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL-1β
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β
12 hours prior to BPD treatment. The cells were then refed with medium containing
both IL-1β and BPD for another 12 hours. Steady-state mRNA levels for IL-6, IL-1β,
MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized to the
expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT and
TMF1 for synovial fibroblasts. Anti-inflammatory activities of BPD were evaluated at
concentration levels of 10-4 M and 10-6 M . Cells treated with BPD showed
significant (p<0.05, *) changes in gene expression compared to control cells with IL1β stimulation alone. No significant difference was observed between the two
different BPD concentrations. Data are expressed as mean+/- SEM of three
biological replicates, with IL-1β positive control cells defined as 1.00.
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B: Synovial fibroblasts
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Figure 17. Effect of two different concentrations of triamcinolone (TA) on
expression of pro-inflammatory biomarker genes in primary articular chondrocytes
(A) and synovial fibroblasts (B) following IL-1β stimulation. Recombinant equine IL1β (1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL1β 12 hours prior to TA treatment. The cells were then refed with medium
containing both IL-1 β and TA for another 12 hours. Steady-state mRNA levels for
IL-6, IL-1β, MMP3, MMP13, and iNOS were measured by RT-qPCR, and normalized
to the expression of reference genes HPRT and EIF2B2 for chondrocytes, and HPRT
and TMF1 for synovial fibroblasts. Anti-inflammatory activities of TA were
evaluated at concentration levels of 10-5 M and 10-6 M
. Cells treated with TA
showed significant (p<0.05, *) changes in gene expression compared to control cells
with IL-1β stimulation alone. No significant difference was observed between the
two different TA concentrations. Data are expressed as mean+/- SEM of three
biological replicates, with IL-1β positive control cells defined as 1.00.
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Effects of glucocorticoids and VBP1 on five pro-inflammatory gene expressions in
primary articular chondrocytes and synovial fibroblasts.
VBP1, a dissociative glucocorticoid, was reported to maintain comparable antiinflammatory efficacy to prednisolone with reduced side effects in muscle cells.
Accordingly, VBP15 shows promise as a potentially safer therapeutic agent for joint
inflammation. Steady-state mRNA levels of 5 pro-inflammatory genes (IL-6, IL-1β,
MMP3, MMP13 and iNOS) were tested using quantitative RT-PCR. MPS, BPD, and TA
significantly (p<0.05) inhibited mRNA of pro-inflammatory genes in both cell types
relative to control cells with IL-1β stimulation alone. There was a significant
(p<0.05) association between different type of glucoocrticoid treatment and
expression of IL-6, IL-1β, MMP3, and MMP13. Significant differences were observed
among MPS, BPD, and TA for IL-6, IL-1β, and MMP3 in chondrocytes (Figure 18A),
and IL-6, MMP3, and MMP13 in synovial fibroblasts (Figure 18B). Comparing VBP1
to three glucocorticoids, anti-inflammatory efficacies of VBP1 were similar to those
of TA, however, significantly lower than MPS and BPD.
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Figure 18. Effects of glucocorticoids and VBP1 on expression of pro-inflammatory
marker genes in primary articular chondrocytes (A) and synovial fibroblasts (B)
following IL-1β stimulation. Recombinant equine IL-1β (1ng/ml) was used as a proinflammatory stimulus. Cells were stimulated by IL-1β 12 hours prior to drug
treatment. The cells were then refed with medium containing both IL-1β and a drug
for another 12 hours. Steady-state mRNA levels for IL-6, IL-1β, MMP3, MMP13, and
iNOS were measured by RT-qPCR, and normalized to the expression of reference
genes HPRT and EIF2B2 for chondrocytes, and HPRT and TMF1 for synovial
fibroblasts. Methylprednisolone (MPS, 10-6 M), betamethasone
(BPD, 10-6 M),
and triamcinolone
(TA, 10-6 M) significantly (p<0.05，*) inhibited proinflammatory gene expression in both cell types relative to control cells with
IL-1β
stimulation alone. Significant differences were observed among different
drug treatment groups for IL-6 and MMP3 in both cell types, IL-1β in chondrocytes,
and MMP13 in synovial fibroblasts. Comparing VBP1
to three glucocorticoids,
anti-inflammatory efficacies of VBP1 were similar to those of TA, however,
significantly lower than MPS and BPD. Data are expressed as mean+/- SEM of three
biological replicates, with IL-1β positive control cells defined as 1.00.
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iNOS gene expression and inducible nitric oxide synthase activity
Steady-state mRNA level of iNOS was significantly increased by IL-1β
stimulation (more than 100-fold) in primary articular chondrocytes. The effect of IL1β on iNOS gene transcription was significantly (p<0.05) reversed by
glucoocrticoids (MPS, BPD, and TA) or VBP1 (Figure 19A). VBP1 at the
concentrations of 10-5M or 10-6M both inhibited iNOS gene transcription, however,
significant difference was only observed at 10-5M.
Nitric oxide (NO) production was significantly increased by IL-1β stimulation
(more than 100-fold). The effect was reversed by increasing doses of glucocorticoids
and VBP1. Glucocorticoids and VBP1 reduced IL-1β-induced NO production in a
dose-dependent manner (Figure 19B). BPD and TA significantly (p<0.05) reduced
NO production more than 30% when concentrations increased above 10-8M. MPS at
the concentration levels above 10-6M significantly decreased NO production more
30%. VBP1 also significantly (p<0.05) inhibited NO production when concentration
was increased to 10-5M.
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Figure 19. Effects of glucocorticoids and VBP1 on iNOS gene expression and nitric
oxide production in primary articular chondrocytes. Recombinant equine IL-1β
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were stimulated by IL-1β
12 hours prior to drug treatment. The cells were then refed with medium
containing both IL-1β and a drug for another 12 hours. Steady-state mRNA for iNOS
was measured by RT-qPCR, and normalized to the expression of reference genes
HPRT and EIF2B2. Nitrite in drug treated chondrocytes was assessed at
concentration levels of methylprednisolone (MPS: 10-4 ， 10-6， 10-8， 10-9，or 1010 M), betamethasone (BPD: 10-4 ，10 -6， 10-8， 10-9，or 10-10 M), triamcinolone
(TA: 10-5 ， 10-6， 10-8， 10-9，or 10-10 M) or VBP1 (10-5 , 10-6, 10-7, 10-8, or 10-9
M) by Griess reagents. (A) Steady state mRNA of iNOS was increased by IL-1β
stimulation and the effect was significantly (p<0.05, *) reversed by glucocorticoids
or VBP1 treatment. Data are expressed as mean+/- SEM of three biological
replicates, with IL-1β positive control cells defined as 1.00. (B) Nitric oxide
production was increased by IL-1β stimulation. The effect was reversed by
increasing doses of glucocorticoids and VBP1. Significant differences were observed.
Data are expressed as mean+/- SEM of three biological replicates.
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Type II collagen gene expression in primary articular chondrocytes with
glucocorticoids treatments.
Methylprednisolone, betamethasone, triamcinolone are three commonly used
intra-articular glucocorticoids in horse, yet drug-induced suppression of type II
collagen synthesis by chondrocytes has been documented. VBP1 as a potential
therapeutic agent for joint inflammation may have a reduced side effect on type II
collagen gene transcription. Dose-dependent effects of glucocorticoids and VBP1 on
the steady-state mRNA level of type II collagen in chondrocytes were tested.
Methylprednisolone, betamethasone, triamcinolone, and VBP1 all displayed
numerically lower levels of steady-state COL2A1 mRNA, but not to an extent that
was significantly different from the control samples (Figure 20).
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Figure 20. COL2A1 gene expression in primary articular chondrocytes with
glucoocrticoids or VBP1 treatment. Cells were exposed to four drugs individually at
a concentration level of methylprednisolone (MPS, 10-4 or 10-6 M), betamethasone
(BPD, 10-4 or 10-6 M), triamcinolone (TA, 10-5 or 10-6 M) or VBP1 (10-5 or 10-6 M).
Steady state mRNA for COL2A1 was measured by RT-qPCR, and normalized to the
expression of reference genes HPRT and EIF2B2. Data are expressed as mean+/- SD
of three biological replicates, with IL-1β control cells defined as 1.00.
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HAS2 gene expression in synovial fibroblasts following equine recombinant IL-1β
stimulation and treatment with glucocorticoids.
Hyaluronan (HA), which is produced by synovial fibroblasts, is an important
component of synovial fluid contributing to properties of viscosity and boundary
lubrication. In order to evaluate the inhibition of glucocorticoids and VBP1 on HA,
HA transcription in synovial fibroblasts was analyzed. Hyaluronic acid synthase 2
(HAS2) mRNA levels were significantly (p<0.05) upregulated by stimulation with 1
ng/ml IL-1β, as compared with untreated controls (Figure 21). Methylprednisolone,
triamcinolone, and VBP1 all repressed the HAS2 mRNA levels which were induced
by IL-1β stimulation, and change levels were from 0.7 fold to 0.89 fold (Figure 21).
However, significant difference between these three drugs treated samples and
samples with only IL-1β stimulation was not observed. Betamethasone at
concentration levels of 10-4 M and 10-6 M significantly (p<0.05) down-regulated the
HAS2 mRNA levels (Figure 21).
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Figure 21. HAS2 gene expression in synovial fibroblasts following recombinant IL1β stimulation and glucocorticoids or VBP1 treatment. Recombinant equine IL-1β
(1ng/ml) was used as a pro-inflammatory stimulus. Cells were exposed to 4 drugs
following IL-1β stimulation at a concentration level of methylprednisolone (MPS, 104 or 10-6 M), betamethasone (BPD, 10-4 or 10-6 M), triamcinolone (TA, 10-5 or 10-6 M)
or VBP1 (10-5 or 10-6 M). Steady state mRNA for HAS2 was measured by RT-qPCR,
and normalized to the expression of reference genes HPRT and TMF1. Data are
expressed as mean+/- SD of three biological replicates, with IL-1β positive control
cells defined as 1.00.
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III.

Glucocorticoid-induced chondrocyte cytotoxicity
As a potent anti-inflammatory drug for osteoarthritis, glucocorticoids

effectively reduce expression of matrix metalloproteinases and help in relieving the
symptoms of joint inflammation. However, several side effects of glucocorticoids
including potential cytotoxicity on chondrocytes have been reported. The purpose
of this study is to evaluate the chondrocyte cytotoxicity of different doses of the
three most commonly used corticosteroids with different length of exposure on
equine primary articular cartilage in vitro. Subsequently, chondrotoxicities of
manufacture recommended dosage levels of methylprednisolone, betamethasone,
and triamcinolone are evaluated on normal equine fetlock joints in order to assist
the clinician when using an evidence-based approach to the use of intra-articular
corticosteroid medications.
Methylprednisolone, betamethasone, and triamcinolone induced chondrocyte
cytotoxicity in monolayer and explants culture.
Several in vitro studies have demonstrated conflicting results for the effects of
corticosteroid on chondrocyte cytotoxicity. In these studies, different experimental
models and corticosteroids were used, and different endpoints were chosen. In
order to compare the cytotoxic effects of three commonly used glucocorticoids on
equine articular chondrocytes, the same experimental models were used in our
study, and several different time points and drug concentrations were evaluated. In
chondrocyte monolayer cultures, cell viability decreased below 90% in the presence
of MPS which concentration levels were equal to or higher than 0.8 mg/ml (1.6x10-3
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M) at three hour time point (Figure 22A). After six hours of incubation, cell viability
fell below 90% when MPS concentrations were equal to or higher than 0.2 mg/ml
(4x10-4 M) (Figure 22A). At the highest concentration of 40 mg/ml (8x10-2 M),
almost all of the chondrocytes were dead after 3 hours incubation (Figure 22A).
After 12 hours of incubation, almost all of the cells were dead when MPS
concentrations were equal to or higher than 10 mg/ml (2x10-2 M) (Figure 22A). Cell
death and viability in response to corticosteroid treatment in explants was assessed
by uptake of ethidium homodimer (red) and calcein-AM (green) fluorescent label
respectively (Figure 23). The cytotoxicity curve for MPS treated chondrocyte
explants is quite similar to the curve observed for chondrocytes in monolayer
culture (Figure 22A). According to these two experiments, MPS concentrations
higher than 0.1 mg/ml (2x10-4 M) are cytotoxic to chondrocytes in both monolayer
and explant culture.
Similar cytotoxicity curves were observed for betamethasone and triamcinolone.
At the 3 hour time point, cell viability decreased below 90% when BPD
concentrations were equal to or higher than 6 mg/ml (1.2x10-2 M) (Figure 22B).
After 6 hours of treatment, cell viability fell below 90% when BPD concentrations
were equal to or higher than 2 mg/ml (4x10-3 M) (Figure 22B). At the highest
concentration of 50 mg/ml (1x10-1 M), almost all of the chondrocytes were dead
after 3 hours incubation (Figure 22B). After 24 hours of incubation, almost all of the
cells were dead when BPD concentrations were equal to or higher than 20 mg/ml
(4x10-2 M) (Figure 22B). Chondrocyte cell viability dropped below 90% when TA
concentration increased to 0.08 mg/ml (1.8x10-4 M) after 24 hours treatment
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(Figure 22C). The same to the MPS cytotoxicity experiments, the cytotoxicity curves
for BPD or TA treated chondrocyte explants and monolayer cultures are very similar
(Figure 22B, C). According to these experiments, BPD concentrations higher than 1
mg/ml (2x10-3 M)and TA concentrations higher than 0.04 mg/ml (9x10-5 M), are
cytotoxic to chondrocytes in both monolayer and explants culture.

71

120
3h
6h
12 h
24 h
72 h
Explants

Cell viability (%)

100

80

60

40

20

0
10-9

10-8

10-7

10-6

10-5

10-4

10-3

10-2

10-1

100

Concentration of MPS (M)

A
120

Cell Viability (%)

100

80

60

40

20

0
10-8

10-7

10-6

c
h
o
n
d
r
o
c
y
t
e
10
10
10
s of BPD (
Concentration
-5

-4

3h
6h
12h
24h
72h
Explants

-3

10-2

10-1

100

)

B
120

Cell viability (%)

100

80

60

40

20

0
10-9

10-8

10-7

c
h
o
n
d
r
o
c
y
t
10e
10
Concentration
s of TA (M)
-6

C
c
h
72 o
n
d
r

-5

3h
6h
12 h
24 h
72 h
Explants

10-4

10-3

Figure 22. Methylprednisolone (MPS), betamethasone (BPD) and triamcinolone
(TA) induced chondrocyte cytotoxicity in monolayer and explants culture. Effects of
MPS, BPD and TA on cell viability were assessed at 5 different cultured time points
(3h, 6h, 12h, 24h, 72h) by MTS kit for monolayer cells. For explants culture, cell
viability was assessed at 9 different concentrations by LIVE/DEAD kit at 72h. Data
are expressed as means +/- S.E.M. (n=3, 4).

Methylprednisolone, betamethasone, and triamcinolone induced chondrocyte
cytotoxicity in equine fetlock joints.
Some limitations of in vitro study, however, must be considered. First,
chondrocytes cultures may not reflect the complex and highly differentiated
cartilage tissue. Second, the chondrocytes are stored in the media in a static manner
and diffusion characteristics likely differ in a moving joint. Another limitation is the
use of constant concentration of drug in vitro as a model of the clinical injection,
which is not equivalent to the in vivo joint environment and metabolism. Effect of
glucocorticoids on chondrocte cytotoxicity therefore need to be evaluated in vivo to
see if drugs at the manufacture recommended dosage level would cause cell death in
equine joints.
All experimental procedures were well tolerated by all of the horses and no
evidence of joint inflammation and lameness was observed following the
administration of corticosteroids.
To assess chondrocyte viability, 2μM of Calcein AM and 10 μM of EthD-1 were
used to stain dead cells (Red) and live cells (green), respectively. To quantify cell
viability, the outer contour of the articular cartilage section and the area containing
viable cells were identified manually. Typical confocal microscopy images of cell
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viability within the articular cartilage layer which were intra-corticosteroid treated
(Figure 23 A) and untreated control (Figure 23B), are shown in Figure 23.

A

B

Figure 23. LIVE/DEAD labeling of articular cartilage from equine fetlock joints
treated with 80 mg/joint methylprednisolone (MPS) or saline. Live cells were
stained green by calcein-AM, whereas dead cells were stained red by ethidium
homodimer. A. Equine articular cartilage from a left front fetlock joint of a horse
treated with 80 mg/joint MPS. B. Equine articular cartilage from a right hind fetlock
joint of the same horse treated with saline.

Methylprednisolone acetate (MPA) caused a significant (P<0.05) reduction in
chondrocyte viability compared with the control saline injections (Figure 24). The
average cell death was increased from 12% in controls to 17.4% with 80 mg/joint of
MPA injections. Biological variation was observed when cell death of MPA treated
samples was compared to control samples for each horse. Significant differences
were observed for two horses. The cell death was increased from 11.4% in controls
to 20.9% with MPA injections in one horse, and from 9.6% in controls to 17.7% with
MPA injections in another horse. There, however, is no significant (P>0.05)
difference was observed for the third horse.
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Betamethasone

containing

betamethasone

sodium

phosphate

and

betamethasone acetate caused a significant (P<0.05) reduction in chondrocyte
viability compared with the controls with saline injections (Figure 24). The average
cell death was increased from 13.2% in controls to 18.5% with 12 mg/joint of
betamethasone injections. Biological variation was observed when cell death of drug
treated samples was compared to control samples for each horse. Significant
differences were observed for two horses. The cell death was increased from 15.5%
in controls to 22.6% with betamethasone injections in one horse, and from 10.3% in
controls to 19.5% with betamethasone injections in another horse. There, however,
is no significant (P>0.05) difference was observed for the third horse.
Triamcinolone acetonide (TA) caused a significant (P<0.05) reduction in
chondrocyte viability compared with the controls with saline injections (Figure 24).
The average cell death was increased from 13.1% in controls to 17.1% with 9
mg/joint of TA injections. Biological variation was observed when cell death of TA
treated samples was compared to control samples for each horse. Significant
differences were only observed for one horse. The cell death was increased from
9.4% in controls to 18.3% with TA injections in one horse. There, however, is no
significant (P>0.05) difference was observed for the other two horses.
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Figure 24. Methylprednisolone (MPA), betamethasone (BPD) and triamcinolone
(TA) induced chondrocyte cytotoxicity in articular cartilage from equine fetlock
joints. Intra-articular MPA (80 mg/joint), BPD (12 mg/joint) and TA (9 mg/joint)
were injected into left front and hind fetlock joints for 3 horses, respectively. The
contra-lateral fetlocks (right front, right hind) were received saline injection. Each
horse was received 2 injections with the same drug. Effect of MPA, BPD and TA on
cell viability was assessed 3 days after the second injection by LIVE/DEAD kit.
Significant differences were observed between treated groups and control groups.
Data are expressed as means ± S.E.M (n= 6). The percentages of cell death in each
treatment group are expressed as mean ± S.D in the table.
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Chapter IV Discussion
I.

Establish an in vitro glucocorticoid treatment model

Tissue culture parameters and protocols were compared to develop a model
system for studying the effects of glucocorticoids on primary equine articular
chondrocytes and synovial fibroblasts. Several cell culture methods have been
developed to investigate chondrocyte and articular cartilage biological properties
(Adolphe et al., 1992; Tew et al., 2008). Although nonadherent aggregates and pellet
culture improve the maintenance of chondrocyte phenotype, they slow the cell
growth, yielding lower amounts of cells and RNA for analysis. Alternatively, articular
cartilage can be studied as explant cultures, in which chondrocytes remain
embedded within their own extracellular matrix (Poole et al., 1989). However, many
experimental manipulations are done more easily using isolated chondrocytes
maintained as adherent monolayer cultures (Otero et al., 2012). After considering
these factors and culturing logistics, monolayer cultures were selected for
subsequent experiments in this study.
Length of culture, pro-inflammatory stimuli, and timing of treatments were
compared. The expression patterns of matrix proteases, protease inhibitors, and
cytokines in equine articular chondrocytes were evaluated during a 14 day culture
period to find out when steady state levels of mRNA for target genes of interest
stabilized. This initial culture period prior to introducing an experimental variable
was used to minimize error introduced by the effects of chondrocyte isolation and
cell plating. PCR analysis showed that the expression of all genes of interest was
markedly and differentially affected by tissue digestion, with differences up to 10 to
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15 fold (Martin et al., 2001). Consistent with previous reports (Lin et al., 2008), the
expression of matrix proteinases MMP3 and MMP9 decreased with increasing
culturing period (Figure 12). Our results also indicated that the expression of MMP3
became relatively stable after 5 days in culture, and the expression of MMP9 became
relatively stable after 10 days in culture. Based on these preliminary data, the preculture period for chondrocytes was determined to be 10 days before starting the
treatment or stimulation, to allow cells to adapt to the culture conditions and
eliminate the effects of tissue collection and cell isolation.
Inflammatory cytokines such as Interleukin-1 (IL-1) β and tumor necrosis
factor-α (TNF-α) play pre-eminent roles in joint destruction. In joint diseases, IL-1β
is synthesized by synoviocytes and cartilage chondrocytes (Martel-Pelletier et al.,
1999; Tiku et al., 1992). IL-1β has been commonly used in articular cartilage and
synovial membranes for creation of a joint inflammation model. It has been shown
to be increased in inflammatory conditions and stimulate the production of matrix
degradation enzymes such as matrix metalloproteinase (MMP) (Pelletier et al.,
1993). Lipopolysaccharide (LPS) has similar effects to IL-1β on chondrocytemediated matrix metabolism and is, therefore, a useful experimental inducer of
chondrocyte-generated pathology (Jasin et al., 1983; MacDonald et al., 1994). In
order to establish a joint inflammation model in vitro, our experiments investigated
the changes in pro-inflammatory gene expressions in response to LPS or IL-1β in
chondrocytes and synovial fibroblasts. Similar to previous studies (Jasin et al., 1983;
MacDonald et al., 1994; Pelletier et al., 1993), both IL-1β and LPS were able to
significantly stimulate the inflammatory response in articular chondrocytes and
78

synovial fibroblasts. IL-1β was more potent than LPS, especially in synovial
fibroblasts. However, no significant difference was identified between 1 ng/ml and
10 ng/ml of IL-1β. IL-1β with 1 ng/ml was used to stimulate the inflammatory
response in chondrocytes and synovial fibroblasts for subsequent studies.
Several different in vitro glucocorticoid treatment models were established in
previous studies: pre-treated with glucocorticoids, then started the inflammatory
stimulation (Baundy et al., 2009; 2012; Crofford et al., 2004); stimulated the
inflammatory response first, then post-treated with glucocorticoids (Bertone et al.,
2008; Lu et al., 2011); treated together with glucoocrticoids and pro-inflammatory
mediators (Frisbie et al., 2001; Busscher et al., 2010; Richardson and Dodge, 2003).
Three different glucocorticoid treatment models were compared in our studies. The
length of IL-1β stimulation was controlled to 24 hours. The expression of cytokines,
matrix proteinases and matrix proteins in chondrocytes and synovial fibroblasts
was determined by quantitative real-time PCR. All three models repressed proinflammatory gene expressions induced by IL-1β stimulation, and the expression of
COL2A1 was inhibited in pre-treatment and simultaneous treatment models, not in
post-treatment model. However, significant differences were not identified among
these three models. Previous studies by Lin et al. 2011, also demonstrated that
treating cartilage with glucocorticoids either before or after inflammatory
stimulation significantly reduced glycosaminoglycans (GAG) loss and increased
proteoglycan biosynthesis. It suggested that even when catabolic processes have
already begun in cartilage, glucocorticoid treatment could still suppress GAG loss
and increase biosynthesis. In clinical cases, patients experience joint pain and joint
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swelling, and then clinicians treat the inflammatory joints using anti-inflammatory
medicine. The chondrocytes and synovial fibroblasts used in this study were
isolated from the normal joints without any sign of joint disease. Therefore, these
cells may have different biological properties from cells from inflamed joints in
which inflammatory response has already been initiated.
Based on these preliminary data and clinical cases, the glucocorticoid treatment
models in primary equine chondrocytes and synovial fibroblasts were established.
Primary equine chondrocytes were pre-cultured in cell culturing medium without
passaging for 10 days. After that, IL-1β at 1 ng/ml was used to initiate the
inflammatory response in both cell types. Twelve hours later, cells were treated
with glucoocrticoids in addition to continued stimulation with IL-1β for another 12
hours. The following experiments were performed using this drug treatment model.
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II.

Dose-dependent effects of glucocorticoids on the expression of proinflammatory genes in chondrocytes and synoviocytes.
A major finding of this study was that glucocorticoids can maximally inhibit

pro-inflammatory gene transcriptions in both equine articular chondrocytes and
synovial fibroblasts at lower doses than widely used clinical dosages.
The hallmark of osteoarthritis is loss of articular cartilage structure integrity
and function. In the early stage of disease, multiple structural proteins of the matrix
are actually increased (MacLeod et al., 1998), however, the net outcome is
progressive loss of matrix integrity. The elements which play the most important
role in the degradation of the cartilage matrix are the matrix metalloproteinases
(MMP). Although there are obvious similarities among the MMPs, each MMP has a
preferred substrate that presumably is related to its role in development, normal
tissue remodeling, as well as disease processes. MMP3 (stromelysin 1) is well
characterized in horse cartilage and believed to have the proteoglycans as preferred
substrates (Morris et al., 1994; Richardson et al., 1998; Balkman et al., 1998).
MMP13 (collagenase 3) has type II collagen as a preferred substrate and has been
studied in equine chondrocytes (Caron et al. 1996; Richardson et al., 2000). It is
generally accepted that MMP increases in arthritis and that it specifically increases
in response to many cytokines, which is clear from our results (Figure 15) and those
of others (Richardson and Dodge, 2003; Pelletier et al., 1993, 1994).
While the role of NO in the physiology and pathobiology of equine vascular
reactivity has been the subject of recent research, its role in equine OA pathogenesis
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has received little study. Results of subsequent short-term experiments using IL-1β
stimulated cultures complement previous reports describing NO synthesis by
equine chondrocytes in response to stimulation with proinflammatory mediators
(Frean et al., 1997; Bird et al., 1997). Our results indicated that methylprednisolone,
betamethasone, and triamcinolone attenuated IL-1β induced NO release by primary
equine articular chondrocytes in a dose-dependent manner. It was also confirmed
by our results that IL-1β induced NO release by equine chondrocytes correlates with
a direct stimulation of iNOS gene expression (Figure 19). Real-time qPCR results
indicated that expression of iNOS in chondrocyte was inhibited by all of three
glucocorticoids at 10−6M. In other species, a number of isoforms of NOS have been
described and vary in their sensitivity to glucocorticoids (Caron et al., 1993; Tung et
al., 2002). Many iNOS isolated from mammalian chondrocytes are insensitive to
corticosteroids at modest doses, however, paralleling our findings, equine iNOS
expression is inhibited with high doses of methylprednisolone, betamethasone, and
triamcinolone. These findings may suggest a limited influence of endogenous
glucocorticoids on iNOS expression but that pharmacologic doses are inhibitory.
Glucocorticoids clearly have complex effects on many genes which are
important in the synthesis and maintenance of articular cartilage. The mechanism of
corticosteroid inhibition of matrix metalloproteinase and cytokines synthesis is
probably related to the inhibition of NF-κB-regulated pro-inflammatory transcripts
(Richardson and Dodge, 2003). Because the effects of glucocorticoids on matrixrelated genes are dose-dependent, specific to certain genes and occur through
various mechanisms, it appears that beneficial effects of steroids may be obtained at
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doses that do not adversely affect matrix protein synthesis. The independent
mechanisms also offer the future possibility of independently regulating these genes.
Although it is impossible to directly relate synovial fluid concentrations of
glucocorticoids with those actually affecting the chondrocytes within articular
cartilage, the molar concentrations were approximately 10-3 M to 10-5 M following
intra-articular injection of 100 mg of the steroid. This corresponds to the range of
concentrations

studied

in

our

experiments.

Although

concentrations

of

glucocorticoids that we studied in vitro were close to the range of expected tissue
concentrations seen in vivo, the actual concentrations exposed to the chondrocytes
are not known. It also must be acknowledged that the complexity of glucocorticoid
effects on other cells in the joint may be important in the net therapeutic result.
Dose-dependent effects of glucocorticoids and VBP1 on the steady-state mRNA
level of COL2A1 in chondrocytes and HAS2 in synovial fibroblasts were tested. The
same as the previous studies (Tanimoto et al., 2001; 2010), HAS2 gene expression
was significantly up-regulated by IL-1β stimulation. From the Figure 20, it can be
seen that glucocorticoid treatments suppressed the gene expression of type II
collagen, however, significant differences were not detected (P<0.05). Suppression
of steady-state gene expression of type II collagen wasn’t expected as we
hypothesized. The data was consistent with our previous studies (Figure 14A). In
our drug treatment model comparison experiments, steady-state mRNA level of
type II collagen was only significantly decreased in models with 24h or 36h
methylprednisolone treatment, not in the model with 12h drug treatment (Figure
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14A). One of the reasons is that cells were not treated with glucocorticoids long
enough to see the inhibition of steady-state level of type II collagen mRNA.
Degradation of mRNA is one of the key processes that control the steady-state level
of gene expression. In general, mRNA species with a short half-life were enriched
among genes with regulatory functions, whereas mRNA species with a long half-life
were enriched among genes related to metabolism and structure (extracellular
matrix, cytoskeleton) (Sharova et al., 2009). The mRNA half-life for type II collagen
is about 17 hours in rabbit articular chondrocytes and 18 hours in human costal
chondrocytes (Galera et al., 1992; Goldring et al., 1994; Mark et al., 2004). In this
study, chondrocytes were treated with glucocorticoids for 12 hours, therefore, the
level of type II collagen mRNA was still elevated upon withdrawal of drug treatment.
Our results verified the former studies that type II collagen mRNA, as an important
extracellular matrix protein gene in chondrocytes, has a relatively long half-life
which is longer than 12 hours in equine articular chondrocytes. In this study,
steady-state mRNA of type II collagen was evaluated, however, significant
differences might be detected between control cells and glucocorticoid treated cells
if only newly synthesized type II collagen mRNA were evaluated.
From what we observed, some further experiments could be planned for future
studies. One of the experiments which could be done is using the same drug
treatment model to analyze newly synthesized type II collagen mRNA to see if
glucocorticoids would suppress type II collagen mRNA synthesis or not. The effect
of glucocorticoids on gene expression levels of some other biomarker genes
(aggrecan, type I collagen, link protein) for articular cartilage also could be
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evaluated to see if glucocorticoids alter the differentiated phenotype of articular
chondrocytes or stimulate dedifferentiation into fibroblasts. The other drug
treatment model also could be tested in the future studies. In the previous reports,
chondrocytes were treated with medium containing glucocorticoids for at least 24 h
(Fubini et al., 2001; Richardson and Dodge, 2003; Busschers et al., 2010) prior to
harvesting cells. The length of drug treatment could be extended. Chondrocytes
could be cultured in medium containing glucocorticoids for 24, 48, or 72 hours.
After that, cells could be collected and the effect of glucocorticoids on steady-state
type II collagen mRNA could be evaluated. Then results also could be compared to
12 hour results to see if there is any difference between these two drug treatment
models.
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III.

Glucocorticoid-induced chondrocyte cytotoxicity
The comparison of effects of methylprednisolone, betamethasone, and

triancinolone on equine articular cartilage was conducted in this study. The drug
concentrations used in this study were at the high end of the manufacturer
recommended doses for equine joint injection, which were commonly used by
veterinarians according to a survey paper published by Ferris et al. 2011. Taken
together, all these three corticosteroids have dose-dependent cytotoxic effects on
equine articular chondrocytes in vitro. Manufacturer recommended concentration
levels of these three commonly used intra-articular corticosteroids in equine
practice have cytotoxic effects on equine articular chondrocyte in vivo. The results of
both our in vitro and in vivo studies are consistent (Table 7).
Corticoidsteroid
Methylprednisolon
e

Clinical
dose
(mg)
40-120

In vivo
Cytotoxicity
conc.(mg/joint)
80

Betamethasone

3-18

12

Triamcinolone

6 -18

9

In vitro
Cytotoxicity
conc.(mg/ml)
0.2

Duration of
action
Medium

2

Medium to
long

0.08

Long

Table 7. Concentrations of glucocorticoids which have cytotoxicity in vitro and in
vivo, as well as commonly used corticosteroid concentrations for horse OA
treatment.

Corticosteroid medications are often injected into the joint space to decrease
joint inflammation. Even though there is evidence that these medications effectively
reduce patient symptoms (Blyth et al., 1994; Cole et al., 2005; Pelletier et al., 1994),
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little is known with regard to their potential cytotoxicity on chondrocytes.
Concentration-dependent cytotoxicity of methylprednisolone on chondrocytes
monolayer cultures was observed by Fubini et al. 2009 and Seshadri et al. 2009, and
these results were consistent with our studies. A recent investigation by Dragoo et
al. 2012, examined the effect of a single dose of betamethasone, methylprednisolone,
and triamcinolone on monolayer cultures of human chondrocytes. The authors
found betamethasone to be significantly cytotoxic to chondrocytes when compared
with controls (Dragoo et al., 2012). The same results were also observed in both our
in vitro and in vivo studies. The cytotoxic effects of methylprednisolone and
triamcinolone on chondrocytes were not reported in Dragoo’s study. However,
several studies, including our investigations, have also shown detrimental effects of
triamcinolone on chondrocyte viability (Celeste et al., 2005; Choi et al., 2005; Syed et
al., 2011). It is reported by Syed et al. 2011 that triamcinolone alone or combination
with bupivacaine was cytotoxic to chondrocytes when compared with controls.
These results partially corroborate our findings, however, some in vivo studies
demonstrated that triamcinolone may not have detrimental effects in patients with
osteoarthritis (Pelletier et al. 1995) and may actually contribute to histopathological
improvements in a canine model of osteoarthritis (Raynauld et al., 2003). The
conflicting results observed in this study coupled with the published reports
indicate that a cautious clinical approach may be best when evaluating indications
for the use of triamcinolone and methylprednisolone for intra-articular injections.
Our study represents a direct assessment of chondrocyte viability after defined
exposure to three corticosteroids individually using quantitative evaluations. The
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major advantage of this study was that chondrocyte viability was evaluated in both
in vitro and in vivo. Multiple drug concentrations and different drug treatment
points can be tested in chondrocyte cell cultures. Animal models precisely maintain
the in vivo condition of chondrocytes within articular cartilage bathed in synovial
fluid, physical pH, and drug diffusion in joint spaces. Some other advantages of this
study protocol include contra-lateral control and consistency over experimental
conditions and direct quantitative measurements of chondrocyte viability using
fluorescent staining. Cytotoxicity of methylprednisolone on equine articular
cartilage in vivo was reported by Chunekamrai et al. according to the histological
staining

results

(Chunekamrai

et

al.

1989).

The

concentration

of

methylprednisolone (120 mg/joint) used in that study, however, was higher than
the commonly used clinical dosage, and the appearance of empty lacunae at the
histological level may not be directly related to the effect of the corticosteroid. In
our study, two florescent dyes were used to visualize the dead and live cells (Figure
11), and the percentages of cell death were quantified using Image J.
Variability was observed in our study. Chondrocyte cell death was also
observed in our control samples with only saline and antibiotic injections. The
average chondrocyte viability of controls in all treatment groups was about 87%
which is lower than that in the explants without any injections (Table 8). Since
same tissue collection, dissection, and staining processes were performed for
explants and equine fetlock cartilage samples, the increased cell death in equine
fetlock cartilage without any corticosteroid treatment may have been caused by the
injection process and/or combined antibiotic injections. However, chondrocyte
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viability at 84% for control samples cultured in saline solution was reported in a
published study (Seshadri et al., 2009). This level is lower than the chondrocyte
viability in our control samples. In future studies, chondrocyte viability needs to be
tested in joints without any injection and with only saline treatment.
Treatment arms
Normal saline
injection
Non-injection

Experimental group
Control samples in
methylprednisolone group
Control samples in
betamethasone group
Control samples in
triamcinolone group
Explants plug

Viability (%)
88%
87%
87%
93%

Table 8. Percentage of live chondrocytes in parallel control joints with normal saline
injection and in methylprednisolone, betamethasone, or triamcinolone treatment
groups, and in explants control sample without any treatment.

The potential for artifacts introduced during tissue processing also need to be
considered. Cut edges were avoided during the imaging of stained articular cartilage
samples (Figure 4). Dead cells were observed along the cut surface of the deep zone
of cartilage, and they were consistent in control and treated sample. Chondrocyte
viability for tissues from the superfacial layer down to the calcified cartilage was
compared to a subsection of each sample limited to 75% of the cartilage that
eliminated the cut surface of the deep zone. Correlation analysis was conducted for
each treatment group. Dead cells in full thickness samples were well correlated to
those

in

75%

of

cartilage

tissues.

The

correlation

coefficients

for

methylprednisolone, betamethasone, and triamcinolone are 0.85, 0.90 and 0.96,
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respectively (Figure 25). Statistical analysis was also performed using student t-test,

20

10

0
0

10

20

30

Dead cells in 75% of samples (%)

40

Betamethasone
30

20

10

0
0

10

20

30

Dead cells in 75% of samples (%)

40

Dead cells in full thickness samples (%)

Methylprednisolone
30

Dead cells in full thickness samples (%)

Dead cells in full thickness samples (%)

demonstrating no significant difference (P>0.05).

Triamcinolone
50
40
30
20
10
0
0

10

20

30

40

50

Dead cells in 75% of samples (%)

Figure 25. Correlation analysis of dead cells in full thickness equine cartilage
samples and those in 75% of cartilage sampls. A. Methylprednisolone treated equine
fetlock joints. B. Betamethasone treated equine fetlock joints. C. Triamcinolone
treated equine fetlock joints.

Limitations of this study include the small number of biological replicates.
Three biological replicates with paired comparisons were used for in vivo
experiments in this study. Obviously, biological variation was observed for all of the
treatment groups (Figure 24). By including more biological replicates for each
treatment group, more statistical power would be achieved. Another limitation is
that the cytotoxicity of corticosteroids on chondrocyte was tested in healthy equine
fetlock joints rather than inflamed joints that would be selected for treatment in
clinical situations. Effusion and changes in drug pharmokinetics in inflamed joints
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might alter the results. Further studies, therefore, may need to be conducted to
evaluate the cytotoxicity of corticosteroid on inflamed chondrocytes.
Taken together, this study clearly shows a decrease in chondrocyte viability
after exposure to corticosteroid treatments both in vitro and in vivo. The critical
finding from this study is that the manufacture’s recommended dose of
methylprednisolone, betamethasone, and triamcinolone can cause cell death and are
cytotoxic to chondrocytes. As such, the data support using the lowest concentration
of corticosteroids possible to achieve desired clinical goals.

Copyright © Wenying Zhu 2015
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Chapter V Conclusion
I.

Reflections
Research efforts in this dissertation thesis were aimed at examining important

questions related to the chondrocyte cytotoxicity and anti-inflammatory efficacy of
glucocorticoids used in the treatment of equine synovial joint inflammation. The
primary hypothesis of this work was that manufacture’s recommended dose of
glucocorticoids currently used in equine clinical practice exceed the amount
necessary to achieve maximal anti-inflammatory efficacy. In addition, these levels
are cytotoxic to articular chondrocytes. To test this hypothesis, experiments were
designed to characterize changes in steady state mRNA for targeted gene transcripts
in chondrocytes with glucocorticoid treatments and to evaluate drug-induced
cytotoxicity both in vitro and in vivo. Within this dissertation results have been
reported for experiments that have been performed to meet the following two
objectives: 1) compare the dose-dependent anti-inflammatory profiles of MPS, BPD,
and TA in synoviocytes and chondrocytes, 2) evaluate glucocorticoid-induced
chondrocyte cytotoxicity in chondrocytes, articular cartilage explants and equine
fetlock joints. By focusing on these objectives, the goal is to generate scientific data
to provide a reference for administrating intra-articular glucocorticoid injections in
equine practice.
Intra-articular glucocorticoid injections are commonly used to treat synovitis
and OA in horses. Since side effects of glucocorticoid on articular cartilage and
underlying bone have been reported, detrimental side effects remain a major
concern among the equine practitioners.
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These side effects are drug- and dose-

dependent, so research is needed to define whether the manufacture’s
recommended dose of glucocorticoids are above a therapeutic optimum in terms of
relative anti-inflamamtory efficacy and chondrocyte cytotoxicity. We described the
first study to examine the three glucocorticoids (MPS, BPD, and TA) induced equine
articular chondrocytes cytotoxicity both in vitro and in vivo. Live/Dead assay was
used to evaluate the chondrocyte cytotoxicity. The results from in vitro and in vivo
studies were consistent. Dose-dependent effects of glucocorticoids on chondrocyte
cell death were observed in chondrocyte monolayer culture and cartilage explants.
With the increase of concentration of glucocorticoids at ranges commonly used in
equine practice, the percentage of chondrocyte cell death increased. This study
supported the hypothesis that manufacture recommended dosage of MPS, BPD, and
TA can cause chondrocyte cell death. According to the results from our study
testing the anti-inflammatory efficacy of glucocorticoids, glucocorticoids were able
to maintain the full functional efficacy at the low concentration levels. Since the
survival of articular chondrocytes is essential to maintain cartilage function, the
data support using the lowest concentration of corticosteroids possible to achieve
desired clinical goals.
II.

Looking ahead to future studies
Follow-up studies to those described in the dissertation should focus on two

areas: 1) determination of effects of glucocorticoids on the expression of biomarkers
for articular chondrocytes. 2) evaluation of effects of dissociative glucocorticoids on
pro-inflammatory gene and type II collagen gene expression in articular
chondrocytes.
93

Effects of glucocorticoids on the expression of biomarkers for articular chondrocyte
Dose-dependent effects of glucocorticoids on the steady-state mRNA level of
type II collagen in chondrocytes were tested. It has shown that glucocorticoid
treatments suppressed the gene expression of type II collagen, however, significant
differences were not detected (P<0.05).
From what has been observed, further research on chondrocyte cell biology is
needed. Since both detrimental (Dahlberg et.al., 2000; Dechant et al., 2003; Sandler
et al., 2004) and chondroprotective (Pelletier et al., 1989; Williams et al., 1985) roles
of glucocorticoids for cartilage have been reported, it would be interesting to detect
the effects of glucocorticoids on articular cartilage by measuring newly synthesized
mRNA of cartilage biomarkers. Type II collagen is the principle collagen of articular
cartilage and plays an essential role in maintaining cartilage architecture and
biomechanical performance. Aggrecan is the major proteoglycan in the articular
cartilage and interacts with hylauronan and link protein to endow the cartilage with
load-bearing properties. Link protein is also essential for normal biomechanical
function of articular cartilage. It can attach the aggrecan to hyaluronan thus forming
the supermolecular aggregate. In the light of their important role in articular
cartilage, it is important to understand how glucocorticoids affect transcription of
cartilage biomarkers, such as with nuclear run-on assay.
Nuclear run-on is used to measure the transcriptional activity of specific genes
in intact nuclei (Bates et al., 2002; Laufs et al., 1999). It provides information on the
synthesis of a specific gene, other than a change in mRNA degradation, transport
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from the nucleus to the cytoplasm, or steady state mRNA (Figure 26). The same drug
treatment model in this study, therefore, can be used to analyze effects of three
glucocorticoids on newly synthesized mRNA of type II collagen, aggrecan core
protein and link protein. The first step of the nuclear run-on assay is the isolation of
intact nuclei of treated cells. And then the nuclei are incubated with four
ribonucleotide triphosphates including radialabelled UTP. This allows the
transcription of a labeled total mRNA over a defined time in vitro. After that, the
radiolabeled RNA is isolated and hybridized with appropriate DNA sequences
immobilized on a membrane (Figure 26). The DNAs usually include the sequences of
target genes and of an endogenous control gene as a standard. The amount of
specifically hybridized RNA proportional to the standard and therefore reflects the
transcriptional activity of genes in the intact cell.

Gene B
Gene A

Not being transcribed
Actively transcribed

Isolate nuclei

Gene A

Gene B
Allow to “run-on”
in presence of
radio-labeled
nucleotides

Hybridize to specific
probes

Figure 26. Schematic diagram of the process of nuclear run-on.
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Effects of dissociative glucocorticoids on pro-inflammatory gene and type II collagen
gene expression in articular chondrocytes
One of the dissociative glucocorticoids, VBP1, has been tested in this study.
VBP1 significantly inhibited the iNOS gene transcription and NO production.
However, the suppression effects of VBP1 on several pro-inflammatory gene
transcriptions in articular chondrocytes were not significant. There remain some
questions to the mechanism of action of the VBP compounds on chondrocytes.
VBP1 is one of Lazaroid ∆-9,11 analogs and is a water-insoluble compound
with poor solubility in organic solvent. It is also reported recently that VBP1 can
bind to both glucocorticoid receptor and mineralocorticoid receptor with relatively
high affinity (Reeves et al. 2013). Another dissociative glucocorticoid, VBP15 which
is a lead compound of the ∆-9,11 steroids, has been reported to inhibit the
production

of

NFκB-regulated

pro-inflammatory

transcripts

in

human

macrophages (Dillingham et al. 2015), bronchial epithelial cells (Damsker et al.
2013), and skeletal muscle cells (Heier et al. 2013). VBP15 showed greater affinity
for the glucocorticoid receptor and lower affinity for mineralocorticoid receptor
than other ∆-9,11 steroids (Heier et al. 2013), indicating that VBP15 has the
possibility to be a potential candidate for OA therapy. Although VBP15 is also a
water-insoluble compound, it has better solubility than VBP1 and can be solved in
8% DMSO + 8% Ethanol + 50% PEG400 + 34% HP-β-CD (20% W/V) (Reeves et al.
2013), which makes VBP15 as a better candidate that can be tested than VBP1.
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Since anti-inflammatory efficacy of VBP15 has been reported in several cell
types, it would be interesting to address the effect of VBP15 on NF-κB-regulated
pro-inflammatory transcripts in chondrocytes. Chondrocytes can be transfected
with NF-κB luciferase reporter plasmids (Rockel et al. 2008, Feng et al. 2003). Cells
expressing NF-κB luciferase reporter will be cultured for the luciferase assay. Drug
treatment model in the published study (Baudy et al. 2009) will be adopted. Cells
will be treated with VBP15 at the concentration level of 10-5 M for 24 hours. After
that, TNF-α at the concentration level of 10ng/ml will be used to induce the NF-κB
transcription and cells will be treated with TNF-α for 24 hours. Commercially
available C2C12 cells that expressing NF-κB response elements coupled to
luciferase in which VBP15 inhibit the NF-κB luciferase activity (Baudy et al. 2009)
will be used as a positive control. Cells with only TNF-α treatment will be used as a
negative control. Luciferase values will be normalized as a percentage of TNF-α
treated only group. This study could be used to determine if VBP15 can inhibit the
NF-κB transcription in chondrocytes and chondrocytes are refractory to VBP15.
Additionally, effects of VBP15 on pro-inflammatory and chondrocyte biomark
genes transcription can be evaluated as well. To confirm effects of VBP15 on NF-κB
target genes in chondrocytes, several inflammatory transcripts such as IL-1β, IL-6,
Cox2, iNOS, MMP3, and MMP13 can be assayed by Real-time qPCR in VBP15 and
MPS treated chondrocytes. One of the reported detrimental effects of
glucocorticoids on articular cartilage is that glucocorticoids suppressed the
transcription of type II collage. In order to evaluate the detrimental effects of
VBP15 on articular cartilage, type II collage transcription can be analyzed in VBP15
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treated chondrocytes. Inhibition effects of VBP15 on type II collage transcription in
chondrocytes will be compared to those of MPS treated groups.
Glucocorticoids are important drugs in joint inflammation therapy. Although
they have strong anti-inflammatory efficacy, several detrimental side effects are
identified. Most of anti-inflammatory effects are mediated by transrepression,
while many side effects are due to transactivation. Dissociative glucocorticoids,
such as VBP15, can induce transrepression with little or no transactivation activity.
Accordingly, dissociative glucocorticoids may be potential agents for joint
inflammation therapy. This study may be able to provide molecular insight into the
molecular mode of dissociative glucocorticoids activities in joint tissues.

Copyright © Wenying Zhu 2015
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